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ABSTRACT 
 
The Bioactive Properties of Syringomycin E-Rhamnolipid  
Mixtures and Syringopeptins 
 
by  
 
Mekki F. Bensaci, Doctor of Philosophy 
Utah State University, 2009 
 
Major Professor: Dr. Jon Y. Takemoto   
Department: Biology 
 
The need for new antimicrobial agents has become important in the last decade 
due to emerging resistance to a number of conventional antimicrobial agents. New 
approaches and sources are needed to generate novel and effective antimicrobials.  For 
example, synergistic combinations between two or more agents may lead to new 
antimicrobial therapies.  Furthermore, the increase in health problems caused by the 
exposure to agricultural crop pesticides and synthetic fungicides and the emerging 
development of organic farming has increased the necessity to develop natural products 
than can be used safely in controlling crop diseases. 
In this work, I present the first studies on the bioactive properties, particularly 
fungicidal activities, of mixtures of SRE and rhamnolipids.  The in vitro results clearly 
showed strong synergism between SRE and rhamnolipids against phytopathogenic fungi 
and yeast. However, no activity was observed against bacteria.  The hemolytic activities 
and cytotoxicities of SRE and SYRA were dose dependent.   
 iii 
SRE acts on yeast and plant plasma membranes to cause numerous cellular 
effects. The effects are consistent with SRE’s ability to form ion-conducting voltage 
sensitive channels in membrane bilayers.  In addition, studies with yeast have revealed 
that sphingolipids and sterols modulate the fungicidal activity of SRE.  Saccharomyces 
cerevisiae sphingolipid and sterol biosynthetic mutants were used to investigate the 
mechanism of action of SYRA against fungi. These results suggest that similar to SRE, 
SYRA antifungal action is promoted by sphingolipids and sterols of the plasma 
membrane and involves pore formation.  
 I further explored the antimicrobial spectrum of syringopeptin SP25A and show that 
it specifically inhibits Gram-positive bacteria and yeast.  I also investigated its 
mechanism of action against yeast and bacteria. The results revealed the role for D-
alanylation of teichoic acids in modulating the susceptibility of B. subtilis to SP25A and 
other syringopeptins.   This is consistent with the charged nature of the cyclic peptide 
portions of the syringopeptins, and it provides an explanation for SP25A’s higher degree 
of specificity for Gram-positive bacteria. In addition and similar to SRE, SP25A 
antifungal action is promoted by sphingolipids and sterols of the plasma membrane and 
involves pore formation.  
 Overall, the research shows that SRE and rhamnolipids are synergistically active 
against yeast and fungi and that the syringopeptins have antimicrobial activities against 
yeast and Gram-positive bacteria.  Insights into the mechanisms of action of the SRE and 
rhamnolipid mixtures and the syringopeptins and their potential as novel antimicrobial 
agents are revealed.  
(173 pages). 
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
 
Cyclic Lipodepsipeptides of Pseudomonas syringae pv syringae 
 
The phytopathogenic strains of Pseudomonas syringae pv. syringae produce two 
major groups of cyclic lipodepsipeptides: the small cyclic lipodepsinonapeptides and the 
larger syringopeptins (2, 11, 83).  Individual P. syringae pv. syringae isolates typically 
produce one of a variety of forms of the syringopeptins and one form of the smaller 
lipodepsinonapeptides (6, 74). 
Four groups of small cyclic lipodepsinonapeptides are well known: 
syringomycins (Fig. 1.1), syringostatins, syringotoxins and pseudomycins (31).  They all 
contain a long, unbranched-3-hydroxy fatty acid, with a positively charged and a 
hydrophilic cyclic ring of nine amino acids at the C terminus (31, 74).  These small cyclic 
lipodepsipeptides are considered to be antifungal (31).  They exhibit fungicidal activity 
against various yeast and filamentous fungi such as Candida, Cryptococcus, Geotrichum, 
and Aspergillus species (11, 23).  Previous studies showed that these compounds tend to 
be more active against yeasts than against filamentous fungi (54, 76).  Inhibitory 
activities against bacteria are not typically observed for the cyclic lipodepsinonapeptides 
(47).  In addition to their antifungal activities, the cyclic lipodepsinonapeptides are 
hemolytic and cytotoxic to mammalian cells (22, 76).  
The syringopeptins (SPs) are larger and more hydrophobic than the cyclic 
lipodepsinonapeptides.  The best-studied syringopeptins are SP22 and SP25 (Fig. 1.2) 
(4).  Structural analyses of these metabolites using 1H and 13C NMR (2) and tandem mass 
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spectrometry (2) revealed that SP22 and SP25 possess 22 and 25 amino acids, 
respectively (Fig. 1.2).  The amino acids are predominantly hydrophobic with a 
prevalence of valines and alanines.  About 70% of the chiral amino acids residues are of 
the D configuration, and there are four α,β-unsaturated and two 2,4- diaminobutyric acid 
residues (2, 4, 32, 70).  An N-terminal amino acid dehydroaminobutyric acid (Dhb) is N-
acylated by a 3-hydroxylated fatty acid chain containing ten and twelve carbon atoms 
giving homologs designated A and B, respectively, and typically the more abundant and 
less abundant forms, respectively.  The C-terminal carboxyl group is esterified by the 
hydroxyl group of the alloThr residue positioned at the distance of seven residues, thus 
forming an eight-membered lactone macrocycle.  Recent studies have shown that SPs 
have antimicrobial activity against Gram-positive bacteria Bacillus megaterium and 
Micrococcus luteus (54).  However, the activities against other bacterial species have not 
been reported.  The SPs are also antifungal but with less potency than the small cyclic 
lipodepsipeptides. 
Other species of Pseudomonas such as P. syringae pv. atrofaciens (87),  
P. fuscovaginae (5), P. tolaasi (66) and P. corrugata (28) also produce cyclic 
lipodepsipeptides (CLPs) that have antimicrobial properties.  Studies by Vassilev et al. 
(87) showed that P. syringae pv. atrofaciens, the causal agent of basal glume of cereals 
and grasses, also produces SRE and SP25A.  P. fuscovaginae, the causal agent of 
bacterial brown sheath, produces syringotoxin and fuscopeptins (5, 30).  Structure 
analysis revealed that the fuscopeptins structure differs slightly from SP22.  The 
fuscopeptin lactone ring contains five amino acids rather than eight in the case of SP22.  
However, Like SPs, fuscopeptins have a high content of hydrophobic amino acids and 
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amphiphilic properties (5).  The biological properties of the fuscopeptins more closely 
resemble those of the SPs than of the cyclic lipodepsinonapeptides (5, 30).  The 
phytopathogenic bacterium from tomato, P. corrugata (69, 28) produces cyclic 
lipodepsipeptides known as corpeptin (MW 2121) and cormycin (MW1274).  Structural 
analysis of corpeptin (CP) and cormycin (CM) revealed that overall these two are 
structurally similar to SPs and lipodepsinonapeptides, respectively.  The main differences 
between CM and small lipodepsipeptides were attributed to the molecular net charge and 
the nature of the amino acids occurring at positions 2–6 (69).  The CP peptide moiety and 
fatty acid moiety show very high homology to those of the SPs (28). Additionally, CP 
and CM display antimicrobial activities against bacteria and yeast (28, 69).  The 
antimicrobial activities of CP and the SPs are similar.  It was shown that CP was more 
active against Gram-positive bacteria than against yeast (28).  Interestingly, Scaloni et al. 
(69) also showed that CM inhibits both bacteria and yeast.  The antibacterial observation 
was not consistent with the antimicrobial activities of the other small lipodepsipeptides.  
CM also exhibited phytotoxic effects and hemolytic activity (69).  Finally, Scaloni et al. 
(69) have shown that CM forms pores in planar lipid bilayers and its primary target is the 
plasma membrane. 
 Recent studies by De Bruijn et al. (21) using genomic analyses have revealed new 
CLPs produced by the bacterium strain P. fluorescens SBW25.  Structure analyses 
revealed that the CLPs produced by SBW25 contain 9 amino acids linked to 3-
hydroxydecanoic acid.  The structural features of SBW25 CLP are closely similar to 
another CLP produced by P viscosa called viscosin (55).  In addition, the bioactivity 
studies showed that the SBW25 CLPs play roles in motility, biofilm formation and also 
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have antifungal activity against zoospores of Phytophthora infestans (21).  This discovery 
shows that genome analyses are useful tools that complement structural analyses for 
finding new antibiotics produced by microorganisms. 
 
Biosynthesis of Cyclic Lipodepsipeptides 
The biosynthesis of the cyclic lipodepsipeptides is a non-ribosomal, template-
directed process.  Certain enzymes – but not all - responsible for cyclic lipodepsipeptide 
production have been identified (11, 35).  The biosynthesis of SRE has been the most 
thoroughly studied among the cyclic lipodepsipeptides.  
SRE synthesis takes place on a multienzymatic thiotemplate. Analysis of the syrB 
and syrC genes of P. syringae pv. syringae indicates that syringomycin is synthesized by 
a thiotemplate mechanism (89).  The syringomycin (syr) gene cluster contains a DNA 
region of approximately 37 kb on the chromosome of P. syringae pv. syringae B301D 
(36, 89).  The gene cluster encodes four proteins (SyrB1, SyrB2, SyrC and SyrE) 
involved in biosynthesis (36, 89).  The syrE gene encodes a 1,039 kDa synthetase 
containing eight amino acid activation modules (36).  The syrB gene represents an operon 
that expresses two proteins (89).  SyrB1 is a 68 kDa protein that carries adenylation and 
thiolation domains, and the 35 kDa SyrB2 protein (11).  The syrC gene is located 
between the syrB operon and syrE (36).  The syrC gene encodes a 48 kDa protein similar 
to several proteins containing thioesterase enzyme motifs (86).  The syrD gene encodes a 
63 kDa protein that is involved in secretion of syringomycin E and is a member of the 
ATP Binding Cassette transporter protein family (65). 
The regulatory mechanisms for SRE production are complex.  The regulation of 
syringomycin production by P. syringae pv. syringae is modulated by both nutritional 
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factors and plant signal molecules (34).  For example, iron exerts a positive regulatory 
effect on SRE production, whereas inorganic phosphate represses the production (35).  In 
addition, plant signal molecules such as arbutin also play a role in SRE synthesis.  The 
syr gene cluster contains a regulatory gene called syrP that is responsible for the control 
of SRE production (91).  SyrP is a 40 kDa protein that may function in a phosphorelay 
signal transduction pathway (65, 90), therefore, it is believed to be a component of a 
kinase cascade that regulates syringomycin production.  Another gene, known as syrA , 
identified by Xu and Gross (88), encodes a regulatory protein required for both 
syringomycin synthesis and pathogenicity.  
Global regulation of SRE production has been well studied (44, 68).  The lemA 
and gacA genes encode members of a two-component sensory transduction system of  
P. syringae pv. syringae that regulates toxigenesis and the ability to cause necrotic 
lesions in plants (44).  LemA is a transmembrane histidine protein kinase activated by an 
extracellular signal that phosphorylates GacA (44, 68).  GacA is assumed to function as a 
transcriptional activator (68).  The LemA-GacA protein pair appears to be at the top of 
the regulatory hierarchy controlling SRE production (11).  Strains with mutations in 
either GacA or LemA do not produce syringomycin E. Kitten et al. identified salA as a 
member of the lemA-gacA regulon that can restore SRE production if it is overexpressed 
(52).  Also, it was reported that the expression of syrB-lacZ was reduced to less than 3% 
in a salA mutant (52).  The predicted SalA protein sequence exhibits an H-T-H DNA-
binding motif with similarity to response regulators (3).  It remains to be determined if 
SalA binds directly to the promoter region of syrB operon or activates the operon 
indirectly through intermediate regulators such as SyrP (52) (11).   
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SPs are also synthesized by non-ribosomal mechanisms and multienzymatic 
peptide synthetases (73).  Mapping and sequence analysis have indicated that the syp 
gene cluster is located adjacent to the syr gene cluster (11, 37).  Almost the entire syp and 
syr gene clusters are located on approximately 145 kb DraI fragment on the chromosome 
of P. syringae pv.syringae (73).  The syp gene cluster is estimated to encompasss 80 kb 
of DNA, and 70 kb of DNA from this region is dedicated to encoding peptide 
synthetases.  Mutations located in regions encoding peptide synthetase disrupted either 
syringomycin or SPs production indicating that these two are synthesized by separate 
peptide synthetase systems (73).  The syr-syp gene cluster contained genes of phytotoxin 
regulation (syrP, salA, syrF,and syrG) and secretion (syrD), in addition to syringomycin 
and  SP biosynthesis genes (syrE, syrB1, syrC, and sypA) (72).  Guenzi et al. (36) showed 
that SypA, SyrB, and SyrC exhibit 45.5, 45.6, and 45.9 % identity, respectively to SyrE, 
and 42.7, 44.3, and 43.3 % , respectively to SyrB1, both of which are syringomycin 
synthetases.  SP is produced under the same conditions as syringomycin.  It was 
suggested that the synthesis of SP is activated by the same regulatory system that 
regulates syringomycin (11).  
 
Syringomycin E Mechanism of Action 
 
 Physiological studies.  SRE produced by P. syringae pv. syringae is the best 
studied of the small cyclic lipodepsipeptides.  Recent studies with SRE have focused on 
the antifungal mechanism of action of the small cyclic lipodepsinonapeptides (40).  The 
amphipathic lipopeptide structure of SRE promotes its interaction with the plasma 
membrane as the first site of action (11).  Previous work by Zhang and Takemoto (92) on 
Rhodotorula pilimanae showed that SRE causes an increase in tetraphenylphosphonium 
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uptake indicating an increase in membrane potential (92).  This results in a variety of 
effects such as K+ effluxes and H+ influx which eventually result in cell death (93).  In 
plants, SRE induced stomata closing in Xanthium strumarium and Vicia faba by causing 
K+ efflux (59).  A reversal effect was observed when fusicoccin was applied.  This result 
leads to an argument that SRE does not permanently disrupt the plasma membrane (59).  
Other studies show that SRE collapses the pH gradient across the plasma membrane by 
inducing K+ efflux and H+ influx (11, 67, 92).  Moreover, it was also shown that H+-
ATPase activities of R. pilimanae and red beet storage tissue were stimulated by SRE 
(13).  However, no stimulation was observed when purified enzyme was used; this 
suggests that SRE’s stimulation effect was not directly on the enzyme and that other 
components are involved.  In addition to K+ and H+ exchange, SRE also stimulates Ca2+ 
influx (84, 85).  Studies with syringomycin E-treated red beet storage tissue have shown 
an overall increase in Ca2+ uptake (84, 85).  The influx of Ca2+  was followed by a cascade 
of events associated with cellular signaling in plants (84) such as the induction of kinase-
mediated phosphorylation of membrane proteins (H+-ATPase) (13) and the incorporation 
of 1,3-B-callose into plant cell walls (11, 51). 
 Bilayer studies.  In recent years more studies were done to characterize SRE 
channel formation and properties using artificial lipid membranes.  Studies by Hutchison 
and Gross (45) and Feigin et al. (29) revealed that SRE forms voltage-dependent channels 
in artificial planar bilayer membranes.  These studies revealed that SRE forms non 
specific pores which are permeable to both monovalent and divalent cations.  It was 
shown that at least six SRE molecules are required for channel formation and the pore 
radius was estimated to be 1 nm (29) (18) (46).  In addition, Ostroumova et al. (62) 
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showed that SRE channels are larger at the trans side with radii of 0.5-0.9 nm versus 
0.25-0.35 at the cis side, concluding that the SRE channel is asymmetrical.  Additional 
studies showed that SRE forms two types of channels, “small” and “large” differing 6 to 
7 times in their conductance (49, 71).  The SRE channels cluster transiently and exhibit 
synchronous channel opening and closing resulting in the wide range of conductances 
(49).  In addition, these channels display temperature-dependent pore inactivation (58, 
71, 81) .  
 
The Roles of Yeast Sphingolipids and Sterols   
 In yeast, sphingolipids and sterols play important roles in the action of SRE.  
Sphingolipids are major components of the eukaryotic plasma membrane, and they 
represent about 8 % of its total mass (42, 63).  The sphingolipids are composed of a long 
chain base with an amide-linked fatty acid at the C-2 position and a polar constituent at 
the C-1 position.  Sphingolipids are ubiquitous in eukaryotes, and they play roles in many 
cellular functions such as protein glycophosphatidylinositol (GPI) anchoring, heat stress 
responses, and modulation of membrane enzyme activities (27, 64). 
The biosynthesis of S. cervisiae sphingolipids has been well elucidated, and the 
major functional genes for sphingolipid biosynthesis have been identified  
(Fig. 1.3) (26).  The first step of sphingolipid biosynthesis begins with condensation of 
palmitoyl-CoA and serine to form 3-ketodihydrosphingosine (14).  The condensation 
reaction is catalyzed by a multi-subunit membrane enzyme serine palmitoyl transferase. 
In S. cerevisiae this enzyme is encoded by LCB1 and LCB2 (9, 15, 60).  The next step of 
sphingolipid biosynthesis involves the reduction of 3-ketodihydrosphingosine to 
dihydrosphingosine by the NADPH-dependent reductase TSC10 (80).  In yeast this is 
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followed by conversion of dihydrosphingosine into phytosphingosine by hydroxylation at 
the C4 position of the sphingoid base by the SYR2/SUR2 gene product (17, 27, 33, 38).  A 
special feature of sphingolipids is its very long fatty acyl side chain that contains 24 to 26 
carbons atoms.  The synthesis of these long chains is done by the ELO2 and ELO3 that 
convert C16 and C18 fatty acids to C20 and C26 sphingolipid molecules (Fig. 1.3).   
In addition,  the FAH1 is responsible for α-hydroxylation of the amide linked very long 
chain fatty acids. 
Three main forms of sphingolipids are formed in S. cerevisiae 
inositolphosphorylceramide (IPC) (78), mannosyl-inositolphosphorylceramide (MIPC), 
and mannosyl-diinositolphosphorylceramide (M(IP)2C) (75) (Fig. 1.3).  The formation of 
these three lipids requires successive additions of phosphorylinositol, mannose and a 
second phosphorylinositol to ceramide.  First, the transfer of  phosphorylinositol from 
phosphatidylinositol to ceramide is catalyzed by IPC synthase encoded by AUR1 (60).  
Then, a mannose group is added to IPC to form mannosylinositolphosphoceramide 
(MIPC).  This step in yeast requires the genes CSG1 and CSG2 (9) (10).  Finally, the last 
step in sphingolipids biosynthesis is the transfer of phosphorylinositol to M(IP)2C.  This 
step is catalyzed by M(IP)2C synthase, the encoded protein of SYR4/IPT1 (27, 56). 
Findings with S. cerevisiae mutants resistant to SRE have shown that structural 
features of sphingolipids and sterols are involved in SRE’s mechanism of action  
(Fig. 1.4).  For instance, one of the genes that promotes SRE action is SYR1/ERG3, which 
encodes the sterol C5,6 desaturase for the biosynthesis of ergosterol, the primary sterol in 
yeast plasma membrane (82).  The expression of specific sphingolipid biosynthetic genes 
SYR2, FAH1, ELO2, ELO3 CSG1, CSG2 and IPT1 also promote SRE action.  A mutation 
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in any one of the genes causes no cell lethality, but each renders resistance to the killing 
effects of SRE (40, 79).  In addition, the work of Kaulin et al. (50) revealed that the C4-
OH sphingoid base is important for SRE channel forming ability and a mutation in the 
C4-hydroxylase gene SYR2 causes a reduction in the number of pores formed by SRE. 
 
Mechanism of Action of Syringopeptins 
 
Despite the structural differences between SRE and the SPs, both elicit similar 
physiological and membrane biophysical responses. Several studies have shown that the 
SPs are capable of forming ion conducting membrane pores (19, 45).  The amphipathic 
nature of the SPs facilitates their insertion into lipid bilayers causing channel formation 
and disruption of the membrane.  In plant systems, the SPs have been shown to cause 
electrolyte leakage in leaf tissues, which leads to the development of necrotic symptoms 
(47).  In addition, Di Giorgio et al. (25) have shown that the SPs can alter the distribution 
of H+ across the plasma membrane of maize cells and promote stomatal closure in 
Xanthium strumarium leaves.  The SPs also induce lysis and generate a rapid influx of 
45Ca2+ across the plasma membrane of tobacco protoplasts (45).  In yeast, SP action is 
promoted by sphingolipids and sterols of the plasma membrane (Bensaci et al., 2008 
submitted and Chapter 4, this dissertation).  Finally, the SPs interact with the bacterial 
cell surface teichoic acids (12) but the mechanism of interaction with bacterial 
membranes is still unknown. 
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Biosurfactants 
 
Diversity, Properties, and Roles  
 
Biosurfactants are a structurally diverse group of surface active molecules 
synthesized by a variety of microorganisms (bacteria, yeast and fungi) (24, 77).  
Biosurfactants are categorized mainly by their chemical composition and their microbial 
origin (7).  There are six types of biosurfactants: lipopolysaccharides, glycolipids, 
lipopeptides-lipoproteins, phospholipids, and hydroxylated and cross-linked fatty acids 
(mycolic acids) (7, 24).  The biosurfactants are amphiphatic molecules.  As a 
consequence, these molecules have the ability to reduce surface and interfacial tensions 
in both aqueous solutions and hydrocarbon mixtures (8).  In addition, biosurfactants  are 
biodegradable, low in toxicity, ecologically acceptable, and can be produced from 
renewable substrates (57). In nature the functions of biosurfactants are not clear (77)   
However, it has been proposed that biosurfactants play a variety of roles that include: a) 
enhancement of bioavailability and biodegradation of slightly soluble organic carbon 
sources such as petroleum hydrocarbons (77) (b) attachment and detachment of bacterial 
cells to surfaces (77), and defense strategies against other microbes (c) (77).  
Biosurfactants are also used in cosmetics, health, pharmaceuticals, agriculture, and the  
food industry (57).  
 
Rhamnolipids 
Among the glycolipid biosurfactants, rhamnolipids are the most studied. 
Rhamnolipids are produced by certain Pseudomonads and were first described in 1949 by 
Jarvis et al. (48).  Their biosyntheses have been well studied by Hauser and Karnovsky 
and Burger et al. (16, 41) .  Rhamnolipids are secreted by Pseudomonas aeruginosa 
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during the stationary phase of growth under limiting conditions of nitrogen and iron (41, 
61).  The synthesis of rhamnolipids proceeds by sequential glycosyl transfer reactions, 
each catalyzed by specific rhamnosyltransferases with TDP-rhamnose acting as a 
rhamnosyl donor and  
3-hydroxydecanoyl-3-hydroxydecanoate serving as the acceptor (53, 61).  Structural 
analysis revealed that glycolipid biosurfactants are formed by the linking of rhamnose to 
fatty acids composed of saturated or unsaturated alkyl chains with lengths between C8 
and C12 (Fig. 1.5) (39).  Their molecular weights range from 504 to 650 (78, 94). 
 
Antimicrobial Activities of Rhamnolipids 
Rhamnolipids possess antimicrobial activities (39).  They are active against 
zoosporic plant pathogens such as Phythium and Phytophthora species (77).  
Rhamnolipids are also active against fungal species such as Fusarium solani and 
Penicillium funiculosum (1, 39).  Haba et al. (39) have shown that rhamnolipids also have 
antibacterial activities against certain Gram-negative and Gram-positive bacteria.  Among 
the Gram-negative and Gram-positive bacteria tested, Klebsiella pneumoniae, 
Entrobacter aerogenes, Bacillus subtilis and Micrococcus luteus were the most sensitive 
to rhamnolipids (1, 39).  However, no activity against yeast was observed (1, 39).  The 
mechanism of action of rhamnolipids against fungi is still unknown.  However, 
Stanghellini et al. (77) suggested that the rhamnolipids inhibit zoosporic fungi by 
disrupting the zoospore plasma membrane. 
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Crop Fungicides 
Fungicides are extensively used in agriculture for a number of purposes including 
protection of crops, seedlings, and storage.  About 150 different fungicidal compounds 
are currently used with a global market value of about 6 billion U.S. dollars accounting 
for almost 20% of the agrochemicals market (43).   
Fungicides can be classified in two groups based on their source: synthetic 
organic chemicals and naturally-derived fungicides (20).  Organomercurials were the first 
synthetic organic chemicals used as agrofungicides in the early twentieth century (20).  
Later, varieties of organic fungicides were introduced such as: ferbam, ziram, and 
dinocap.  These compounds are known to be multisite inhibitors.  They disturb fungal 
physiology by interacting with functional groups of enzymes and other key constituents 
of fungal cells (20).  Their non-selective action sometimes cause undesirable effects in 
plants, mammals, and beneficial organisms (20).  Therefore, in the early 1960s, new 
measures and regulations were adopted to limit the use of these fungicides and to 
promote the search for novel fungicides with specific target sites (20).  The search 
resulted in the discovery of specific-site fungicides such as the benzimidazoles, N-
arylcarbamates, sterols and melanin biosynthesis inhibitors, phenylpyrroles, 
dicarboximides, and other fungicides such as aromatic hydrocarbons (20).  However, due 
to the increase in resistance, side effects in mammals and wildlife with extensive use, and 
the low biodegradability of these compounds (20), a new effort was promoted to screen 
microbial products in order to discover new natural compounds that are highly 
biodegradable and low in toxicity.  The search led to the first discovery by Takeuchi et al. 
in 1958 of blasticidin A (20).  This fungicide is produced by Streptomyces 
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griseochromogenes.  It was used for the control of rice blast disease caused by 
Pyricularia oryzae.  Following this discovery more fungicides of microbial origin such as 
kasugamycin, polyoxins, validamycin A, and mildiomycin were discovered and used in 
agriculture (20).  Prior to 1970, most of the used fungicides were multisite inhibitors. 
Resistance to these compounds is rare.  However, with the use of site specific fungicides 
the rate of resistance increased dramatically and the time between commercial 
introduction and the emergence of resistance was much shorter than with the multisite 
fungicides.  A good example of resistance is the outbreak of benzimidazole resistance of 
Cercopsora beticola in sugar beet and the loss of matalaxyl control of Phytophthora 
infestans (43).  Fungicide resistance can have significant impacts on agriculture and crop 
protection that include economic loss.  Awareness of these problems led researchers to 
define the factors which influenced the spread of resistance and to seek strategies to 
combat it (43).  However, resistance is not the only factor to limit the use of particular 
fungicides.  Selectivity and the distinct spectra of activity are a concern because most 
specific site fungicides have limited use against certain important plant pathogens (20).  
These problems raise the call for new and effective fungicides with broad spectra and no 
resistance.  
 
Justification and objectives for the present research 
 
The need for novel  antimicrobial agents has become important in the last decade 
due to emerging resistance to a number of conventional antimicrobial agents. New 
approaches and sources are needed to generate novel and effective antimicrobials.  For 
example, synergistic combinations between two or more agents may lead to new 
antimicrobial therapies.  Furthermore, the increase in health problems caused by the 
 15 
exposure to agricultural crop pesticides and synthetic fungicides and the emerging 
development of organic farming has increased the necessity to develop natural products 
than can be used safely in controlling crop diseases. 
The overall aim of the research is to investigate the bioactive and synergistic 
properties (particularly fungicidal activities) of mixtures of the cyclic 
lipodepsinonapeptide SRE and rhamnolipids.  Being natural products, there is interest in 
the commercial applications of both compounds as fungicides.  Both are physically and 
chemically similar with the ability to be extracted and processed using similar procedures 
from cultures of fluorescent pseudomonads.  Rhamnolipids are now commercially 
available, and industrial production of SRE is under development.  If synergistic, the 
mixtures of the two could have major applications in agricultural crop disease control as 
well as other important applications involving control of fungal growth.  In the present 
research, the bioactive properties of SRE, rhamnolipids, and combination mixtures of the 
two were investigated.  
The objectives of the research were to study: 
1) the parameters of SRE-rhamnolipid mixtures (SYRAs) that give optimal 
antimicrobial activities against yeasts, fungi and bacteria, 
2) the spectrum of fungal species that are inhibited by SYRAs, 
3) the fungicidal mechanism of action of SYRAs, 
4) the toxicities of SYRAs on mammalian cell lines, red blood cells, and 
honeybees. 
5) the possibility of other pseudomonad cyclic lipodepsipeptides having 
synergistic antimicrobial activities when combined with rhamnolipids. 
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FIG. 1.1.  Structure of the cyclic lipodepsinonapeptide syringomycin E. Dab:2,4 
diaminobutyric acid; Dhb:dehydroaminobutanoic acid; Asp(OH): β-OH aspartic acid; 
Thr(Cl): 4-chlorothreonine. 
 
 
 
 
 
FIG. 1.2. Structure of syringopeptin. R = CH3- (CH2) n-CH (OH)-CH2CO, SP22A (n=6), 
SP25A(n=6)Abbreviation Dab=1,4-diaminobutyricacid; Dhb=2,3 dehydroaminobutyric acid; all 
other amino acids are identified by standard three letter biochemical notation. 
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FIG. 1.3.  Diagram of sphingolipid biosynthesis in S. cerevisiae 
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FIG. 1.4.  The S. cerevisiae sphingolipid M(IP)2C. The enzymes that modify precursors 
of M(IP)2C during its biosynthesis are shown and the structural modification indicated 
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FIG. 1. 5. Chemical structures of rhamnolipids produced by Pseudomonas aeruginosa 
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CHAPTER 2 
THE BIOACTIVE PROPERTIES OF SRE AND  
RHAMNOLIPID MIXTURES 
 
Introduction 
 
 
The need for new antifungals and fungicidal biocontrol agents is growing due to 
the narrowing spectra of fungal targets and increasing resistance to existing antifungals 
such as amphotericin B and the azoles (30, 31).  One approach to develop novel 
antifungals is to combine known antifungal compounds.  Such combinations may have 
improved bioactivities and expanded target spectra due to the synergy between the 
compounds.  Moreover, lower effective doses of the combination components may have 
less toxicity.   
The plant bacterium Pseudomonas syringae pv. syringae produces an array of 
antimicrobial peptides known as the small cyclic lipodepsipeptides such as syringomycin, 
and the large cyclic lipodepsipeptides known as the syringopeptins (3, 38).  The small 
cyclic lipodepsipeptides contain an unbranched-3-hydroxy fatty acid with a positively 
charged cyclic ring of nine amino acids at the C terminus (14, 32).  Their molecular 
weights range from 1000 to 1300 (14, 32).  The best studied is SRE.  Previous studies 
showed that SRE has inhibitory activity against fungi and yeast such as Botrytis cinerea, 
Geotrichum candidum and Rhodotorula pilimanae (21, 38).  It tends to be more active 
against yeasts than against filamentous fungi (21).  Recent studies have focused on the 
antifungal mechanism of action of the small cyclic lipodepsinonapeptide SRE (16) was 
shown to form channels in phospholipid bilayers, and it is speculated that a similar 
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mechanism occurs in the target fungal membrane (7).  Channel formation may cause the 
influx of ions such as K+ and Ca2+ (38). 
Many strains of Pseudomonas aerginosa produce several homologs of the 
biosurfactant known as rhamnolipid (1, 15).  Rhamnolipids were first described in 1949 
by Jarvis  and Johnson (20) and their biosyntheses was well studied by Hauser and 
Karnovsky (17).  Rhamnolipids are glycolipids secreted at the stationary phase of growth 
under limiting conditions of nitrogen and iron (17, 28).  Structure analysis revealed that 
these compounds are formed by rhamnose linkage to fatty acids of saturated or 
unsaturated alkyl chain between C8 and C12 (15).  Their molecular weights range from 
504 to 650 (37, 41).  The antimicrobial activities of rhamnolipids are well studied.  They 
are active against zoosporic plant pathogens such as Phythium and Phytophthora species 
(35).  Rhamnolipids are also active against fungal strains such as Fusarium solani and 
Penicillium funiculosum (1, 15).  Moreover, Haba et al. (1, 15) have shown that 
rhamnolipids also have antibacterial activities against certain gram-negative and gram-
positive bacteria.  Among the gram-negative and Gram-positive bacteria tested, 
Klebsiella pneumoniae, Enterobacter aerogenes, Bacillus subtilis and Micrococcus luteus 
were the most sensitive to rhamnolipids (15).  However no activity against yeast was 
observed (1, 15). 
The main objective of this study was to examine the in vitro interaction of SRE 
and RL against bacteria, yeast, and filamentous fungi.  I investigated the antimicrobial 
properties and cytotoxicity of syringomycin E (SRE), rhamnolipids (RLZonix) and the 
mixture SYRA (3:1 mixture of RLZonix and SRE).  Synergistic antifungal activities 
between SRE and RLZonix in the mixtures (SYRAs) were observed.  The SRE minimal 
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inhibitory concentrations (MICs) were lowered when combined with RLZonix.  However, 
no activity was observed against bacteria.  In vitro cytotoxicity and erythrocyte lysis were 
also investigated.  The hemolytic activity and cytotoxicity of SRE, RLZonix and SYRA 
were dose dependent.  However, the concentrations of SRE and SYRA that caused 
hemolysis and cytotoxicity were 3 to 5 times higher than the MICs.  In addition, the 
honeybees toxicity effect of SRE, RLZonix, and SYRA was also studied.  The use of most 
pesticides in agriculture has often negative effects against bee populations and 
ecosystems.  The ecological and agricultural importance of bees requires the use of safe 
and less toxic fungicides.  The results showed no toxicity at concentrations higher than 
the MICs. 
 
Materials and Methods 
 
 
SRE and Rhamnolipids 
SRE was purified from P.syringae pv.syringae strain B301D by the method of 
Bidwai et al. (4). P.syringae pv.syringae strain B301D was grown in non-commercial 
potato dextrose casamino acids medium in 4 or 8-liter cultures as described by Zhang 
et al. (40).  The SRE was extracted from cultures using acidified acetone and purified 
using the chromatographic methods described by Bidwai et al. (4).  HPLC column 
fractions were tested for bioactivity by applying 10 µl aliquots on a fresh lawn of R. 
pilimanae on potato-dextrose agar plates, incubation at 28oC, and observing cleared 
growth inhibition areas (40). 
The rhamnolipids (RLZonix) was obtained from Jeneil Biotech, Inc. Zonix contains 
8.5 % solution of rhamnolipids in water.  Two forms of rhamnolipids are in zonix , 
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R1 (C26H48O9) has the molecular formula of α-L-rhamnopyranosyl-β-
hydroxydecanoyl-β-hydroxydecanoate,R2(C32H58O13),2-O-α-L-rhamnopyranosylα-L-
rhamnopyranosyl- β  hydroxydecanoate. 
 
Organism and Media 
The following organisms were obtained from the microbial culture collection of 
the Department of Biology, Utah State University:  R. pilimanae ATCC9449, Candida 
albicans ATCC10231, Aspergillus flavus, Aspergillus niger, Rhizopus stonifer, Fusarium 
oxysporum, Rhizoctonia solani, Botrytis cinerea, Cladosporium cladosporioides, 
Penicillium oxalicum, Penicillium sp.  All fungi were cultivated in potato dextrose 
medium (Difco) (PDA) at 28 to 30°C.  Saccharomyces cerevisiae W303C, S. cerevisiae 
BY4741 and S. cerevisiae 8A-1B were obtained from Dr. Takemoto’s laboratory 
collection.  S. cerevisiae strains were grown on YPD at 28°C.  S. aureus ATCC653, B. 
subtilis ATCC1965, E. coli ATCC25922, Proteus vulgaris ATCC13315.  The bacteria 
strains were grown at 37°C for 24 h on Luria-Bertani medium except S. aureus was 
grown on Mueller-Hinton medium. 
 
Antifungal Susceptibility  
 Agar disk diffusion method.  The disk diffusion assay was done according to 
National Committee for Clinical Laboratory Standards (NCCLS) protocols for antifungal 
testing with modification (26) (25).  Fungal isolates were subcultured on PDA plates and 
incubated for 3 to 5 days at 35°C.  The fungal plates were covered with 5 mL of distilled 
sterile water.  Then, the fungal spores were harvested and suspended in sterile water.  The 
suspension was adjusted to 106 spores/ml (36).  A 100 µl of the suspension was 
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transferred and spread uniformly onto solid agar of the appropriate growth medium using 
cotton swabs (36).  
To test the antifungal activity of SRE in combination with RLZonix, 10 µl of SRE 
(1 mg/ml) was applied on disk and placed on plates containing different concentrations of 
RLZonix (22).  Another test was done by applying SRE and RLZonix to a different disk.  The 
distance between the disks was equal to the sum of radii of zones of inhibition of the 
drugs applied alone.  The plates were incubated for 24 to 72 h at 35°C (5) and the zone of 
inhibition was measured.  To examine the effect of varying the SRE and RLZonix 
concentrations in SYRA, 4 mm diameter sterilized paper disks were deposited on the 
surface and 10 µl of different ratio of SRE and RLZonix mixtures were applied. 
Tested bacteria were grown in LB broth for 24 h and transferred onto solid agar 
medium of the appropriate growth medium.  The cultures were spread over the surface as 
a thin film (39).  Four mm diameter sterilized paper disk was deposited on the surface 
and 10 µl of SRE, RLZonix and SYRA were applied.  The plates were incubated for 24 h at 
37°C and the zone of inhibition was measured. 
Hyphal extension assay.  The hyphal extension essay was done as described by 
Dash et al. (9) with modification.  A 100 µl of 1 ×106 spores/ml suspension was paper 
strip in a middle of the Petri dish and incubated for 48 h until the appearance of the 
growing hyphae.  Sterile filter disks (4mm diameter) were deposited in the front of the 
growing hyphea and 10 µl of tested solutions were applied to each disk.  The plates were 
further incubated at room temperature and pictures of the plate were taken at the 
designated time.  
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Spore suspension assay.  The spore suspension assay was performed as 
described by Mauch et al. (23).  The fungal spores were harvested as described 
previously.  The spore suspension was adjusted to 1× 106 spores/ml.  The freshly 
prepared suspension was spread on a Petri dish plate and incubated for 20 to 24 h at room 
temperature.  After this period, four mm paper disks were deposited and 10 µl of the test 
solutions were applied to the disks.  The plates were further incubated and the zones of 
inhibitions were measured after 48 h.  
Microbroth dilution method.  The MICs were determined by the microbroth 
dilution assay according to method outlined by the NCCLS with modification (25, 26).  
The inocula suspensions were prepared as described previously (5).  Fungal isolates were 
subcultured on PDA plate and incubated for 3 to 5 days at 35°C.  The inoculums 
suspensions were prepared from fresh cultures.  The fungal plates were covered with 5 ml 
of distilled sterile water.  Then, the fungal spores were harvested and suspended in sterile 
water.  After harvesting the spores, the conidia suspensions were diluted with RPMI 
medium (RPMI 1640 with L-glutamine buffered to pH 7 with 0.165 M 
morpholinepropanesulfonic acids (MOPS) and  supplemented with 2% glucose) (18, 25, 
29) (HyClone Laboratories) and adjusted to a final concentration of 1 ×105 spores/ml 
using cell counting hemocytometer.  A 50 µl of the conidia suspensions were added to 
each well of 96-well polystyrene microtiter plates (Fisher Scientific catalog no. 21-377-
203) to achieve a 1x 104 concentration with conidia/ml.  Aliquots (50 µl) of twofold serial 
dilutions of SRE and RL were added to each well (100 µl total volume).  The plates were 
incubated for 24 to 72 h at 35°C.  The MIC was defined as the lowest concentration that 
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completely inhibited the growth.  The tests were carried out in three replicates to confirm 
the MIC value.  
For yeast, cells were grown to a final concentration of 108 CFU/ml and suspended 
at a final concentration of 5 x105 CFU/ml.  Cell suspensions (25 ml) were added to 25-ml 
aliquots of two fold serial dilutions of SRE and RLZonix, and appropriate broth media (27) 
were dispensed (100 µl total volume) in wells of 96-well polystyrene microtiter plates 
(Fisher Scientific catalog no. 21-377-203).  The plates were incubated for 24 h at 28°C.  
The colony-forming unit (CFU) experiment was performed under the same 
experimental conditions as described for the microbroth dilution.  In brief, starting 
inoculum of 1-4 x 105 CFU/ml of C. albicans ATCC10231 were treated with different 
concentrations of SRE and SYRA.  The CFU were counted by subculturing 100 µl of 
serial dilution of each well on PDA.  The experiment was performed in three triplicates, 
and the results were reported as mean values.  
Checkerboard microtiter plate testing.  To test the antifungal combinations of 
SRE and RLZonix, a checkerboard microtiter assay was done according to the 
recommendations of the NCCLS for in vitro susceptibility testing (26).  The testing was 
done in RPMI 1640 with L-glutamine buffered to pH 7 with 0.165 M of MOPS 
supplemented with 2% glucose (12).  A 96-well plate was used to determine the 
fractional inhibitory concentration (FICs).  Serial  twofold dilutions of SRE and RLZonix 
was prepared separately.  Then, 25µl of different concentrations of SRE was added in a 
vertical orientation and 25 µl of different concentrations of RLZonix was added in 
horizontal orientation (33).  The conidia and yeast cell suspensions were prepared as 
described previously (36) and 50 µl of the suspensions were added to each well.  The 
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final volume of the well contains 50 µl of the drugs and 50 µl of the tested culture.  The 
plates were incubated for 24 to 72 h at 35°C.  The fractional inhibitory concentrations 
(FICs) of each drug was defined as the MIC of the combination of SRE and RLZonix 
divided by the MIC of the drug alone (12) (33).  Then, the FIC index was calculated by 
adding up the FICs for each of the drugs (33).  The interaction was defined as synergistic 
if the FIC index was <1.0, additive if the FIC index was 1.0, and antagonistic if the FIC 
index was >2.0 (12, 22). 
Time-kill curves.  The time-kill curve assay was done according to methods 
described by Marchetti et al. (22) with modification.  An inoculum of 5 x105 CFU/ml of 
C. albicans ATCC10231 was used under the same experimental conditions as described 
for the microbroth dilution (27).  The effects on viability of SRE (1.97µg/ml) and SYRA 
(0.97 SRE + RLzonix 2.92 µg /ml) after 3, 6, 9, 12, and 24 h of incubation were examined.  
A synergy effect is defined as ≥2 log10 decrease in CFU per milliliter compared to the 
most active ingredient (6, 24). 
 
Toxicity Assays 
Hemolysis assay.  Hemolytic activity was determined by the method described by 
Dartois et al. (8) and Sorensen et al. (34) with modification.  Sheep erythrocytes were 
used to test hemolytic activity of SRE, RLZonix, and SYRA.  Sheep red blood cells (RBC) 
were obtained by centrifuging whole blood at 1,000 × g, washed four times with PBS, 
and resuspended in 10 ml of PBS to a final concentration of 5% of RBC (8).  The RBC 
suspension (80 µl) was added to each well containing different concentrations of SRE or 
RLZonix or SYRA (20 µl).  The plate was incubated at 37°C for 60 min.  Deionized water 
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and triton X-100 1% (w/v) were used as positive controls.  The percent of hemolysis was 
calculated using the following equation:  
% hemolysis= (absorbance of sample) – (absorbance of blank) ×100/ (absorbance of 
positive control).  Fifty percent hemolysis (HD50) values were calculated as the sample 
concentrations required to lyse 50 % of the RBC (8). 
In vitro Cytotoxicity.  The cytotoxicity assay against mammalian cells was determined 
by the method described by Dartois et al. (8).  Cell viability was determined using MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS) and the electron coupling reagent, phenazine methosulfate 
(PMS).  This assay is based on the ability of the cells to convert a soluble tetrazolium salt 
to formazan product.  The cell lines for the cytotoxicity tests were obtained from the Utah 
State University collection. The NIH-3T3 9 (mouse fibroblast), HEK293 and HeLa cells  
(American Type Culture Collection, Manassas, VA) were propagated in culture medium 
containing 90% (v/v) Dulbecco’s modified Eagle’s medium (D-MEM) (Invitrogen, 
Carlsbad, CA), 10 % defined fetal bovine serum (Hyclone Laboratories,Logan, UT). 
MDA-MB-435 cells were cultured in a 1:1 mixture of DMEM and Ham’s F12 medium 
supplemented with 5% (v/v) fetal bovine serum (Hyclone Laboratories, Logan, UT), 1% 
non-essential amino acids, and 1mM sodium pyruvate.  Cells were cultured in Corning 
tissue culture flasks at 37°C with 5 % CO2.  The confluent cells were treated with trypsin-
EDTA and diluted in serum free media.  The cells were transferred into 96-well plates at 
a density of 2×105 cells per well and 20 µl of MTS reagent was added to each well 
containing 100 µl of cells in culture medium.  The cells were incubated in a humidified 5 
% CO2 incubator at 37°C for 3 h (8).  The plates were read with a microplate reader at 
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490 nm.  Percent cytotoxicity was calculated as: (control value − test value) × 100/control 
value.  Lethal concentrations that caused 50% mortality were calculated using Origin 7.0 
(OriginLabCorporation, One Round House Plaza, Northampton, MA 01060). 
Honeybee toxicity.  The test was performed according to methods published by 
the U.S. Environmental Protection Agency (EPA) Office of Prevention, Pesticides, and 
Toxic Substances (OPPTS) with modification (13).  As recommended by the OPPTS, 
Apis mellifera species were used.  Worker honeybees were captured at the entrance of a 
single healthy hive the day of use.  The bees were then brought to the laboratory and kept 
in a small cage at room temperature. Prior to use, all bees in each cage were anesthetized 
with CO2
 
and transferred to three individual cups to have a total of 10 bees in each cup.  
Two tests were performed to test the toxicities of SRE, RLZonix and SYRA.  The first test 
was done by feeding the bees with 200 µl of different concentrations of SRE, RLZonix and 
SYRA (Table.2.4).  For the second test, the bees in each cup were anesthetized again 
with CO2 and different concentrations of SRE, RLZonix and SYRA were applied in 1 µl 
drops to the ventral side of the thorax of each bee. After treatments, the bees were fed 
with 3 ml of sucrose solution (50 % volume of sucrose and 50 % volume of water).  The 
cups were kept at 28°C incubator for 48 h and checked every 4 h.  The ratio of living to 
dead bees was recorded. The treatments with each concentration were replicated three 
times.  
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Results 
 
Antifungal Activities 
The combination of SRE with RLZonix was tested by an agar disk diffusion assay 
in which R. pilimanae was plated onto PDA and PDA with RLZonix (RL-PDA).  Different 
concentrations of SRE were applied on disks and deposited on RL-PDA and PDA.   
The results showed that the zones of inhibition of SRE in RL-PDB were slightly larger 
compared to the agar with no RLZonix (Fig. 2.2).  This indicates some degree of a positive 
interaction between SRE and RLZonix.  However, due to the lower concentrations of SRE 
the zone of inhibition did not increase noticeably compare to the control.  In the 
experiments where SRE and RLZonix were applied to a different disk, no change was 
observed in SRE zone of inhibition (data not shown). 
In this experiment SRE and RLZonix were mixed at different ratios prior to use.  
SRE, RLZonix and SYRA were tested against yeast, fungi and bacteria. SRE and SYRA 
showed antifungal activities against all tested fungi and yeast.  However, no activity was 
observed with RLZonix except against R.pilimanae.  A strong synergy between SRE and 
RLZonix was observed (Fig. 2.1.).  The SYRA activity was much stronger than SRE when 
against tested yeast and fungi.  For example, against C. albicans, the zones of inhibition 
were 20 and 40 mm for SRE and SYRA, respectively (Fig. 2.1, Table 2.1).  In addition, 
the concentration of SRE in SYRA (0.6mg/ml SRE) applied to the disks to give these 
zones of inhibition was 4-fold less than for SRE alone (2.4mg/ml).  It is important to note 
that the highest zones of inhibition against yeast and fungi were obtained when SRE and 
RLZonix were mixed at a ratio of 1:3 (as in SYRA).  No activities were observed against 
tested bacteria. 
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To further investigate the antifungal activity of SRE, RLZonix and SYRA, I tested 
their activity against P. oxalicum, R. stonifer, A. flavus, and A. niger  both hyphal growth 
and germinated spores.  In both experiments, SRE and SYRA were inhibitory against 
germinated spores and hyphal extension of all tested species (Fig. 2.3 and Fig. 2.4). 
However, no activity was observed with RLZonix.  The zones of inhibition were from 15 to 
20 mm against germinated spores.  However, the activity of SRE and SYRA were 
stronger when applied directly after inoculation of the plates (zones of inhibition were 
from 25 to 30mm).  SRE and SYRA inhibited the hyphal growth as it was demonstrated 
by the crescent zone due to the retarded mycelia growth (Fig. 2.4). 
To quantify the antifungal activity of SRE, RLZonix and SYRA, the microbroth 
dilution and the checkerboard methods were used.  SRE inhibited tested fungi and yeast 
with MIC’s that ranged from 1.95 to 7.8 µg per ml (Table. 2.1).  RLZonix did not show 
activity against the tested organisms except R. pilimanae with an MIC of 93.75 µg per 
ml.  However, no antibacterial activity was observed with SRE and RLZonix.  
The SYRA‘s MICs  ranged from 0.5 to 3.9 µg /ml (Table 2.1). Based on the data 
obtained from the checkerboard assay, the FICs indices of SRE plus RLZonix were ranging 
from 0.25 to 0.5 (FIC<1) indicating synergism between these two compounds.  In 
addition, SRE and SYRA showed significant reduction in the viable counts against 
C.albicans (Fig. 2.5). However, SYRA was more fungicidal than SRE alone.  
 
Time Kill Assay 
The synergisms observed between SRE and RLZonix in the checkerboard microtiter 
assay were confirmed in time-kill curves experiments.  Fig. 2.6. shows time-kill results 
for SRE and SYRA.  SYRA was more active than SRE alone and displayed much more 
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rapid killing against C.albicans.  The decreases in CFU with SYRA comply with a 
synergistic relationship between SRE and RLZonix . 
 
In vitro Toxicity Studies 
 
Hemolysis assay.  SRE, RLZonix and SYRA were found to be hemolytic and 
displayed dose dependent hemolytic activity against sheep RBCs (Fig. 2.5).  RLZonix was 
the least hemolytic among the three.  
Cytotoxicity studies.  The cytotoxicity effects of SRE, RLZonix and SYRA on 
mammalian cell lines are shown in Fig. 2.6.  SRE, RLZonix and SYRA displayed a dose 
dependent cytotoxicityagainst NIH-3T3 (mouse fibroblast), HEK293, MDA-MB-435, 
and HeLa cells (Fig.2.6.).  However, the concentrations showing toxic effects on the cell 
lines were higher than those needed for hemolytic activity.  Interestingly, SRE, RLZonix, 
and SYRA displayed more toxicity against the MDA-MB-435 cell line.  The MDA-MB-
435 LC50 for SRE, RLZonix and SYRA were almost three times lower comparing to the 
LC50 of NIH-3T3 (mouse fibroblast), HEK293, and HeLa cells (Table 2.3). 
Honeybee toxicity.  The honeybee toxicity studies of SRE, RLZonix and SYRA 
were examined against Apis mellifera.  The presented results were from three separate 
experiments. The no treatment control had no mortality and the positive control had 
100% mortality after 48 h of observation.  The lethal effect was observed when bees were 
on their back. Table2-4 shows the effects of SRE, RLZonix and SYRA against honeybees.  
The SRE, RLZonix and SYRA were slightly toxic when they were digested by the 
honeybees.  The percentage of mortality was from 20 to 30% after 48 h observation.  In 
contrast, the contact exposure test showed that at the same concentrations, the honeybees 
were indifferent. 
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Discussion 
 
In this work, I studied the antimicrobial activities and the toxicity of SRE, RLZonix  
and the mixture (SYRA).  As expected, SRE was active against a large array of fungi 
including yeasts and filamentous fungi such as C. albicans, Aspergillus spp., and 
Penicillium spp. The MIC’s ranged from 1.95-7.8 µg/ml. However, no activity was 
observed against bacteria. RLZonix did not show antimicrobial activities against most 
tested organisms.  The present study is the first report on the antimicrobial activities of 
SRE and RLZonix combinations.  SRE showed strong synergism with RLZonix for all tested 
yeast and fungi.  Checkerboard analyses showed that RLZonix reduced the SRE MICs two 
to four fold. The FIC indices ranged between 0.25-1 indicating strong synergism between 
SRE and RLZonix.  It is noteworthy that the strongest activity was observed when RLZonix  
and SRE were combined at a 3:1 ratio, respectively.  The mixture at this ratio is termed 
SYRA.  In addition to spore germination inhibition, SRE and SYRA also displayed 
antifungal effects against germinated spores and hyphal growth.  
Interestingly, RLZonix alone did not exhibit antifungal activity against tested fungi.  
However, in the presence of SRE these two showed good synergism.  Antifungal 
synergism was previously observed when amphotericin B was combined with gramicidin 
S or NF against C. albicans  (19).  In contrast, Marchetti et al. demonstrated that despite 
the antifungal activity of combined Fluconazole and cyclosporine (cy) (FLC) against 
C.albicans , the MIC of FLC remained unchanged (22).  However, a fungicidal effect 
was observed after 48 h of exposure to this combination suggesting that perhaps Cy 
action was dependent on the slow effect of FLC on C.albicans cells , and Cy interaction 
with the multidrug transporters rendered C.albicans more susceptible to FLC (22).  Work 
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by Arikan et al. (2) showed favorable interaction between amphotericin B and 
caspofungin against Aspergillus and Fusarium spp (2).  The combination resulted in a 
decrease in amphotericin B MICs (2), and this maybe due to better penetration of 
amphotericin B following the effect of caspofungin on the cell wall (2) .   
 Previous work by Stanghellini (35) showed that RL inhibits zoosporic plant 
pathogens by lysing zoospore membranes.  Both SRE and RLZonix  act on the cell 
membrane but their mechanism of action are different.  The nature of their interaction is 
still under investigation.  One explanation could be that RLZonix interaction with the 
plasma membrane facilitated SRE binding and interaction with the lipid membrane which 
resulted in enhancement of channel formation.  Another explanation is that perhaps the 
anionic characteristic of RLZonix at physiological pH and its interaction with cell surface 
provided more negative charges on the surface which allowed more binding and stronger 
interaction of SRE with the negatively charged membrane causing an increase in number 
of channels formed by SRE.  The mechanism of interaction is still under investigation.  
I also studied the effect of the addition of RLZonix on the hemolytic activity and 
cytotoxicity of SRE.  Previous studies by Sorensen et al. (34) and De Lucca et al. (10) 
have shown that SRE had hemolytic activity against sheep erythrocytes and toxicity on 
HeLa cells.  However, De Lucca and Walsh (11) showed that SRE reduces fungal 
viability by 90 to 98% at concentrations that causes 20% release of hemoglobin from 
sheep erythrocytes.  This result is consistent with my current findings, where SRE MICs 
were 3 to 5 times lower than the concentrations that cause 50% of hemolysis and cell 
toxicity.  In addition, SRE, RLZonix and SYRA effects on honeybees was studied. No 
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effects were observed against honeybees at the concentrations that showed hemolytic and 
cytotoxicity effects.  
In this work, I present the first studies on the antimicrobial activities of SRE and 
RLZonix combinations.  The in vitro results showed clearly strong synergism between SRE 
and RLZonix against phytopathogenic fungi and yeast.  The antifungal spectrum and low 
toxicity suggests that SYRA is a potential candidate for fungicidal agricultural 
applications.  However, more work is needed to better understand the mechanism of 
interaction in vivo. 
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TABLE .2.1.  Antimicrobial activities of SRE, RL and SYRA.  
 MIC (µg/ml) ZI (mm) 
Organism SRE RL 
 
SYRA 
(SRE/RL) 
SRE SYRA FIC 
index 
Aspergillus flavus 7.8 >20 3.9/5.85 11 18 0.5 
Rhodotorula 
pilimanae 
3.9 93.75 0.97/2.92 22 35 0.24 
Candida albicans 3.9 >250 1.95/5.85 21 40 0.5 
Rhizopus stonifer 7.8 >250 3.9/11.7 11.5 20 0.5 
Fusarium 
oxysporum 
7.8 >250 3.9/11.7 10 17 0.5 
Penicillium sp1 7.8 >250 7.8/23.43 10 16 1 
Botrytis cinerea 3.9 93.75 0.975/2.92 13 25 0.24 
Rhizoctonia solani 3.9 >250 1.95/5.85 10 19 0.5 
Cladosporium 
cladosporioides 
3.9 >250 1.95/5.85 15 20 0.5 
Penicillium 
oxalicum 
7.8 >250 1.95/5.85 13 22 0.25 
Saccharomyces 
cerevisiae W303C 
1.97 >250 0.48/1.44 14 25 0.25 
Saccharomyces 
cerevisiae 
BY4741 
1.97 >250 0.48/1.44 13 24 0.25 
Saccharomyces 
cerevisiae 
8A-1B 
1.97 >250 0.48/1.44 15 24 0.25 
Aspergillus niger 3.9 >250 1.95/5.85 11.5 20 0.5 
Staphylococcus 
aureus 
>250 >250 >250 >1 >1 ND 
Bacillus subtilis >250 >250 >250 >1 >1 ND 
Escherichia coli >250 >250 >250 >1 >1 ND 
Proteus vulgaris >250 >250 >250 >1 >1 ND 
MICs values were obtained from triplicate determinations 
The zone of inhibition: The error was ± 2 mm, as determined from triplicate determinations. 
For FIC index calculations with RL, a value of 250 was used for those organisms with an MIC of >250. 
ND, not determined 
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TABLE. 2.2.  Hemolytic activity of SRE, RLZonix and SYRA 
 HD 50% (µg/ml) 
SRE 26 
RLZonix  75.5 
SYRA (SRE) 23 
 
 
TABLE.2.3. Lethal concentration that caused mortality of 50% of the cells. 
Cells  LC50 (µg/ml) 
Hek292 SRE 
RLZonix  
SYRA ([SRE]) 
96 
101 
28.78 
3T3 SRE 
RLZonix  
SYRA ([SRE]) 
100.63 
95.85 
25.40 
Hela SRE 
RLZonix  
SYRA ([SRE]) 
95.85 
96.13 
26.25 
MDA-MB-435   SRE 
RLZonix  
SYRA ([SRE]) 
30.7 
41.4 
12 
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TABLE.2.4. Honeybee mortality  
A- Contact exposure to SRE and RLZonix . 
Time (Hours) 4 12 24 48 
Concentration 
(mg/ml) 
Dead Live Dead Live Dead Live Dead Live 
RLZonix  
12.5mg/ml 
0 10 1 9 2 8 2 8 
SRE 
5 mg/ml 
0 10 1 9 1 9 1 9 
 
B- Feeding SRE and RLZonix   
Time (Hours) 4 12 24 48 
Concentration 
(mg/ml) 
Dead Live Dead Live Dead Live Dead Live 
RLZonix  
12.5mg/ml 
0 10 2 8 2 8 3 7 
SRE 
5 mg/ml 
0 10 1 9 2 8 3 7 
 
D- Contact exposure to SYRA  
Time (Hours) 4 12 24 48 
Concentration 
(mg/ml) 
Dead Live Dead Live Dead Live Dead Live 
SYRA 
(SRE 4.5 mg/ml, 
RLZonix  12.5 mg/ml) 
 
0 10 0 10 0 10 0 10 
 
 
C- Feeding with SYRA 
Time (Hours) 4 12 24 48 
Concentration 
(mg/ml) 
Dead Live Dead Live Dead Live Dead Live 
SYRA 
(SRE 1.6 mg/ml, 
RLZonix  5 mg/ml) 
 
0 10 1 9 1 9 2 8 
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FIG.2.1.  Disk diffusion assay testing the combination of SRE with RLZonix.                              
10 µl of SRE (2.5mg/ml), RLZonix (2.5 mg/ml) and the combination SYRA (0.6mg/ml SRE 
and 1.95 mg/ml RLZonix ), SYRA2 (1.95 mg/ml SRE and 0.6 mg/ml RLZonix ) were applied 
on disks. A- Botrytis cinerea. B-Candida albicans. C-Schizophyllum commun. 
 
A B 
C 
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FIG. 2.2.  Fungicidal activities of different amounts of SRE deposited on PDA containing 
RLZonix against R. pilimanae. Different concentrations of SRE were applied to PDA (A) and 
Agar containing: 10 µg/ml (B), 25 µg/ml (C) of RLZonix .  
Plain agar Agar contains 10µg/ml 
of RLZonix 
Agar contains 25µg/ml 
of RLZonix 
A B C 
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FIG.2.3. SRE and SYRA inhibition against fungal growth. The fungal spores (P. oxalicum, R.  
stonifer) were allowed to germinate on PDA plate and grow for 30 h before SRE (0.25mg/ml) 
and SYRA (0.25mg/ml SRE and 0.75mg/ml RLZonix ), SYRA  
(0.6mg /ml SRE and 1.95mg/ml RLZonix ) were applied on the disks (Column B). Then the 
plates were allowed to grow for 24 h. In column A, SRE and SYRA were applied directly after 
inoculating the plates with fungal spores. RLZonix showed no inhibition.  
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FIG. 2.4. Disk diffusion assay against hyphal extension.  The fungal spores were applied 
to a filter strip and allowed to grow for 48 h until the appearance of hypae. Then, the 
disks were deposited in front of the growing hyphae and 10 µl of SRE (0.25mg/ml) and 
SYRA (0.25mg/ml SRE and 0.75mg/ml RL) were applied.  The plates were incubated for 
another 48 h. RL showed no inhibition. 
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FIG. 2.5.  Effects of SRE (♦) and SYRA(■) on the viability of C. albicans. 
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FIG. 2.6.  Time-kill curves of C. albicans. CFU were determined after 3, 6, 9, 12, and    
24 h of incubation.  Mean CFU values of three separate experiments are shown. Symbols: 
SRE (♦), RL (×), SYRA(■), and control(▲) 
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FIG. 2.7.  Hemolytic activity of SRE (♦), RLZonix (■), and SYRA (▲).  The RBCs were 
incubated for 1 h at 37°C. 
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FIG. 2.8.  Percent cytotoxicity of SRE (■), SYRA (▲), and RLZonix (♦).  
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CHAPTER 3 
 
PHYSICAL-CHEMICAL PROPERTIES OF SRE AND SRE-RHAMNOLIPID  
 
MIXTURES  
 
 
Introduction 
 
 
 In recent years, the need for new and effective agrofungicides has emerged due to 
decreases in the effectiveness and safety of currently used products (10). 
The small cyclic lipodepsipeptide syringomycin E (SRE) contains a long, 
unbranched-3-hydroxy fatty acid with a positively charged and hydrophilic cyclic ring of 
nine amino acids at the C terminus (5, 13).  Previous studies showed that SRE has 
inhibitory activity against fungi and yeast such as Botrytis cinerea, Geotrichum candidum 
and Rhodotorula pilimanae (9, 17)  
The antifungal activity of SRE against a wide range of yeast and fungi, elected it 
to be a possible agrofungicide.  However, its chances to be developed as a commercial 
fungicide agent will strongly depend on its stability under different conditions.   
A comprehensive examination of the literature revealed no publications that describe the 
chemical stability of SRE over a range of pHs and temperatures.  However, Hu et al. (7) 
examined the stability of crude extracts of Pseudomonas species under high temperature, 
and acidic and alkaline pHs.  The results revealed good stabilities of the extract to heat 
and acid but not to alkaline pHs (7).  Furthermore, based on earlier studies on SRE 
activity, it has been observed that SRE solutions had long shelf-lives and remained stable 
for years under dry freezing conditions (unpublished observations, J. Takemoto, Utah 
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State University).  In addition, examination of SRE’s structural features  suggests that it 
would be relatively stable to different temperatures and acidic pHs. 
Rhamnolipids are glycolipids formed by rhamnose linkage to fatty acids of 
saturated or unsaturated alkyl chain between C8 and C12 (6).  Recent studies have shown 
that rhamnolipids are active against zoosporic plant pathogens such as Pythium and 
Phytophthora species (16) and against fungal strains such as Fusarium solani and 
Penicillium funiculosum (6).  In addition, the biosurfactants are known to be effective at 
extreme temperature and pH values (2).  However, very little information has been 
reported on stability of rhamnolipids under different temperatures and pHs.  Thaniyavarn 
et al. (18) have tested the surface tension activity of rhamnolipids over a wide range of 
pHs, temperatures, and NaCl concentrations.  The results showed a significant stability of 
rhamnolipids over all conditions tested.  
 SRE and SRE + rhamnolipid (SYRA) formulations are potential candidates for 
postharvest disease control and possibly other fungicidal applications in agriculture such 
as seed treatment and fruit storage.  In Chapter 2, studies on the bioactive properties of 
both SRE and SYRA were described.  The results showed strong antifungal activities 
against yeast and plant pathogenic filamentous fungi.  It is important to mention that most 
of the experiments were administered in vitro under controlled or optimal conditions.  
However, if used in the field these compounds may be exposed to proteolysis and variety 
of environmental and climate conditions such as high temperatures, humidity and 
different pHs that may abolish or alter their antifungal activities.  Their usefulness as 
agrofungicides requires sufficient stability when subjected to such conditions.  
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 The aim of this study is to examine the physical and chemical stability of SRE 
and SYRA.  To further explore their stabilities and candidacies as agrofungicides, SRE 
and SYRA formulations were exposed to different temperatures and pHs, and subjected 
to autoclaving, ultraviolet light, sonication, and proteolysis.  The treated solutions were 
tested for antifungal activities and analyzed by RP-HPLC in the cases of temperature and 
proteolysis treatments.  In addition, SRE and SYRA were mixed with mineral oil and 
their activities were tested.  The overall results showed significantly high stability of SRE 
and SYRA under the tested conditions.  
 
Materials and Methods 
 
 
SRE and SYRA 
 SRE was purified from P.syringae pv.syringae strain B301D by the method of 
Bidwai et al. (3). P.syringae pv.syringae strain B301D was grown in non-commercial 
potato dextrose casamino acids medium in 4- or 8-liter cultures as described by Zhang 
and Takemoto (19).  The SRE was extracted from cultures using acidified acetone and 
purified using the chromatographic methods described by Bidwai et al. (3).  HPLC 
column fractions were tested for bioactivity by applying 10 µl aliquots on a fresh lawn of 
R. pilimanae on potato-dextrose agar plates, incubation at 28oC, and observing cleared 
growth inhibition areas (19).  Commercial rhamnolipid (Zonix) (RLZonix) was obtained 
from Jeneil Biotech, Inc.  RLZonix is an 8.5% (wt/vol) solution of rhamnolipid analogs in 
water. Two forms of rhamnolipids are in RLZonix, R1 (C26H48O9) has the molecular 
formula of α-L-rhamnopyranosyl-β-hydroxydecanoyl-β-hydroxydecanoate, and R2 
(C32H58O13)  
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is 2-O-α-L-rhamnopyranosylα-L-rhamnopyranosyl- β  hydroxydecanoate.  SYRA was 
prepared by combining SRE and RLZonix at 1:3 (wt/wt) ratios, respectively.  Two 
formulations were used: SYRA0.6, 1.95 (0.6 mg SRE and 1.95 mg RLZonix per ml) and 
SYRA0,25,0.75 (0.25 mg SRE and 0.75 mg RLZonix per ml).  
 
Antifungal Activities 
 
Agar disk diffusion method.  The disk diffusion assay was done accordingly to 
the method described by the National Committee for Clinical Laboratory Standards (1) 
protocols for antifungal testing with modification (11, 15) .  R .pilimanae  was grown in 
potato dextrose broth (PDB)  and adjusted to 5×104 CFU/ml (8, 14) , and transferred onto 
solid agar medium. The culture was spread over the surface as a thin film (14).  Four mm 
diameter sterilized paper disks were deposited on the surface and SRE and SYRA0.6,1.95 or 
SYRA0,25,0.75 were applied on disk1 and disk 2, respectively (7 to 10 µl aliquots). 
HPLC analysis.  The high performance reverse-phase liquid chromatography 
(RP-HPLC) analysis was performed by the method determined by Bidwai et al. with 
modification (3). The treated SRE and SYRA were loaded onto C18 reverse-phase 
column for HPLC analysis. The samples were eluted by a 25 min (0.5ml per min) linear 
gradient of the 70% of 0.1% trifluoroacetic acid in water, and 30% of 0.1% 
trifluoroacetic acid in isopropanol. Eluted SRE and SYRA were detected by UV 
detection at 240 nm. 
Effect of temperature.  SRE (1mg/ml) and SYRA0.25,0.75 solutions were prepared 
and incubated at 4°, 28°, 50°, and 65°C. At 50°C, and 65°C the activities were tested as 
described previously every day for 17 days.  At 4°C and 28°C the activities were tested 
each day for 60 days. The solutions were also autoclaved for 15, 30 and 45 min and their 
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activities were tested against R .pilimanae and 50 µl of the treated SRE solutions or 
SYRA0.25,0.75  were analyzed by RP-HPLC as described previously (3).  In the case of 
SYRA0.25,0.75 , two sample variations were prepared  and used in these experiments. 
Sample A was prepared by mixing SRE (0.25mg/ml) and RLZonix (0.75 mg/ml) after 
autoclaving the individual solutions separately.  Sample B was prepared by mixing SRE 
(0.25 mg/ml) and RLZonix (0.75 mg/ml) before autoclaving. 
Effect of  pH on SRE and SYRA activity.  The effect of pH on the activities of 
SRE (2.4 mg/ml) and SYRA0.6,1.95 was examined using the disk diffusion assay against R. 
pilimanae as described before (12). The solutions were adjusted to pH values of 4, 5, 6, 
and 7 by the addition of 1N HCl or 1N NaOH and incubated at room temperature for 24 
h. Ten µl of SRE and SYRA0.6,1.95   were applied on the disks.  The plates were incubated 
at 28oC for  48 h and the zones of inhibition were measured. 
Effects of ultraviolet light and sonication   
on SRE and SYRA activities.  The effects of UV light and sonication on SRE 
and SYRA activities were studied using the disk diffusion assay against R .pilimanae 
(12).  One hundred µl SRE (2.4 mg/ml) and SYRA0.6,1.95  were added to 96 well-plates 
and irradiated using a Fisher Biotech ultraviolet hand-held lamp (Fisher Scientific) for 60 
min at a wave length of  320 nm. Ten µl of SRE (2.4 mg/ml) and SYRA0.6,1.95  were taken 
every 10 min for 60 min and applied on disks.  The plates were incubated at 28°C for 48 
h and the zones of inhibition were measured.  
Two hundred µl of SRE (2.4 mg/ml) and SYRA0.6,1.95  in 2 ml glass tubes were 
sonicated for different time intervals in a water bath sonicator ( Bransonic ultrasonic 
Model 1210, 50-60Hz).  The 10 µl samples were taken every 10 min for 60 min and 
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tested for activity as described previously.  The plates were incubated at 28°C for 48 h 
and the zones of inhibition were measured.   
 Trypsin treatment.  To study the effect of protease on SRE and SYRA activities, 
the solutions were dissolved in PBS buffer, pH 7.4 in 1.5 mL capacity microcentrifuge 
tubes (20).  Trypsin (bovine pancreas, Sigma, St. Louis) was added at ratio of 1:25 
(enzyme/peptide, w/w).  SRE (1mg/ml) and SYRA0.25,0.75 were mixed with 40 µg/ml and 
10 µg/ml of trypsin, respectively.  The tubes were incubated at 37°C for 2 h and stopped 
by adding trypsin inhibitor aprotinin (Sigma) (10µg/ml). The treated samples were 
examined for their activities against R .pilimanae and analyzed by RP-HPLC as described 
earlier.  
 Effect of mineral oil on SRE and SYRA  
 activities.  SRE and SYRA0.25,0.75  were mixed with mineral oil at a ratio of 1:1 
(vol/vol) and incubated at room temperature for 1 h.  Ten  µl of SRE and SYRA0.25,0.75 
were tested by disk diffusion assay as described earlier.  The plate was incubated at 28°C 
for 48 h and the zones of inhibition were measured.  
 
Results and Discussion 
 
 
Physico-chemical Stability of SRE and SYRA   
The use of SRE and SYRA as fungicides agents requires that they be sufficiently 
stable. Their useful applications will necessitate long-term stability, as well as resistance 
to environmental conditions such as temperature, ultraviolet light, and pH variations. 
The results show that SRE and SYRA0.25,0.75 are stable at 4°C and 28°C (Fig. 3.1). 
However, at 55°C and 65°C, SYRA0.25,0.75  activity began to decrease after 4 days and 
was completely lost after 6 and 11 days at 65°C and 55°C, respectively (Fig. 3.1).  In 
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contrast, SRE remained completely active at these temperatures. It is important to note 
that at 4°C and 28°C SRE and SYRA0.25,0.75 activities were very stable after 60 days of 
incubation (data not shown).  
To further explore the effect of temperature on SRE and SYRA0.25,0.75 activities. 
SRE and SYRA0.25,0.75 were autoclaved for 15, 30, and 45 min at 121°C (Table. 3.1, Fig. 
3.2).  SRE showed full inhibitory activity against R . pilimanae at each time.  In contrast 
the activity of SYRA0.25,0.75 (sample B) declined when autoclaved.  However, when 
SYRA0.25,0.75     prepared with separately autoclaved solutions of SRE and RLZonix (sample 
A), it was active.  To further examine the effect of autoclaving on SRE and SYRA0.25,0.75 
HPLC analyses were performed on treated samples (Fig. 3.3.).  HPLC profiles of RLZonix 
showed that its structure was not affected by autoclaving. However, 60 % of SRE was 
degraded. as a consequence of autoclaving.  In the case of sample B, the SRE structure 
was completely degraded (Fig. 3.3).  It appears that RLZonix interaction with SRE forms a 
complex that is heat sensitive.  It could be speculated that the two molecules physically 
interacted via their hydrophobic and hydrophilic moieties, respectively, and that high heat 
(e.g. autoclaving) disrupts the interactions that are mainly hydrophobic interactions and 
hydrogen bonding.  SRE and RLZonix each showed significant long term stability.  In the 
case of SYRA0.25,0.75, the long term stability was very good at 4°C and 28°C, but, the 
stability began to decline at 55°C and 65°C.  These observations are important for 
considerations of storage and transportation of SYRA formulations. 
To further explore the physical properties of SRE and SYRA0.6,1.95 , these two 
were exposed to UV light, sonication, and varied pHs levels.  The results showed UV 
light and sonication had no effects on antifungal activities against R. pilimanae were not 
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affected by UV light (Fig. 3.5).  SRE and SYRA0.6,1.95  antifungal activities were also 
stable at pHs between 4 and 7 (Fig. 3.4).  However with SYRA0.6,1.95, I observed a 
moderate increase in activity at pH 5 and 6 (Fig. 3.4).  This difference in activity is 
perhaps due to the net charge of RLs.  RL is a anionic biosurfactant with a pKa value of 
5.6 (2).  It was reported by Aranda et al. (2) that at pH 7.4, 98.4 % of the rhamnolipid 
forms are negatively charged, whereas, at pH 4, 97 % are neutral. Possibly, the ratio 
between the anionic and neutral forms have contributed to the activity of SYRA0.6,1.95.  
This information is important for considering pH constraints when combining SRE and 
RLZonix to make SYRA formulations for applications.  The overall results indicate a good 
degree of stability for both SRE and SYRA0.6,1.95  at pH range of 4 to 7. 
The successful use of SRE and SYRA formulations as fungicidal agents may 
depend on environmental and climate conditions such as humidity, radiation, and 
temperature.  Wet and humid conditions may require repetitive treatments to reach the 
desired control.  In addition, this may enhance the effectiveness of fungicides by 
facilitating its spread and penetration into the pathogen.  However, repetitive applications 
might be costly.  Perhaps using mineral oil to deliver these agents may reduce the cost.  
SRE and SYRA were mixed with mineral oil and tested for activity against R. pilimanae . 
The results showed that SRE and SYRA0.25,0.75, were active after mixing them with 
mineral oil (Table. 3.2.). 
 
Effects of Trypsin 
To examine whether SRE and SYRA formulations are stable to protease 
treatment, SRE and SYRA0.25,0.75  were pretreated with trypsin and their antimicrobial 
activities were tested.  The results showed that trypsin treatment did not alter SRE and 
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SYRA0.25,0.75  activities against R. pilimanae.  Moreover, no degradation was observed in 
the tryspin-treated samples.  HPLC analyses showed that the peaks were almost identical 
to the control (Fig. 3.6).  The trypsin is known to cleave at the carboxyl side of both 
lysine and arginine that are connected to other amino acids.  Interestingly, trypsin did not 
cleave the Arg-Phe bond in SRE. Perhaps the nine amino acids cyclic ring and the 
structural conformation of SRE prevented and protected the molecule from trypsin active 
site. This result is consistent with observations of Fernandez-Lopez et al. (4) on 
chemically synthesized cyclic D,L-alpha-peptides. 
 In conclusion, the results of this study provide information on the activities and 
chemical stabilities of SRE and SYRA formulations under a variety of physical 
conditions and chemical treatments.  Overall, SRE and the SYRA show long term 
stabilities.  Their broad spectrum antifungal properties and physical stabilities reinforce 
the prediction that they are promising candidates for use as agrofungicides.  
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Table. 3.1. Effect of autoclaving on SRE and SYRA0.25,0.75  activities 
 
 
                         Zone of inhibition (mm) 
Autoclave time 15 minutes 30 minutes 45 minutes 
 
2.4mg/mlSRE-
Autoclaved 
 
22 
 
20 
 
20 
 
SYRA0.25,0.75 
Mixture B 
 
NI 
 
NI 
 
NI 
 
2.6mg/ml RL 
Autoclaved 
 
NI 
 
NI 
 
NI 
 
SYRA0.25,0.75 
Mixture A 
 
34 
 
32 
 
29 
NI= no inhibition  
 
Table.3.2. Effect of mineral oil on SRE and SYRA0.25,0.75  activities.  
 Zone of inhibition (mm) 
 SRE SYRA0.25,0.75 
 
With mineral oil 22 35 
Without mineral oil 22 35 
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Fig. 3.1. Effect of temperature on SYRA0.25,0.75   activity  4°C(■) , 28°C(♦) , 55°C(●) , 
65°C(▲).SRE activity (○)  4°C , 28°C , 55°C , 65°C ( SRE activity was the same for all 
temperatures) 
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Fig. 3.2.  The antifungal activity of SRE, RL, and SYRA against R .pilimanae.after 
autoclaving. Ten µl of SRE, RL, SYRA0.25,0.75 mixture A (SYRA)  prepared after 
autoclaving the components SRE and RL
 Zonix and SYRA0.25,0.75  mixture B (SYRA’) 
mixed before autoclaving) were applied on disks placed on a lawn of  
R .pilimanae. 
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Fig. 3.3.  HPLC analyses of : (A) SRE 1mg/ml, (B) RLZonix 0.75mg/ml (the arrows 
represent rhamnolipid isomers RL1 and RL2), and  (C) SYRA0.25,0.75 .    (---) 
before autoclaving  and (−) after autoclaving.  Shown are the HPLC profiles 
obtained using a C18 column with a 25 minute of 0-70% gradient  2-propanol in 
0.1% TFA. 
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Fig. 3.4.  The effect of pH on SRE (█), and SYRA0.6,1.95  (▓)  antifungal activity against  
R .pilimanae 
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Fig. 3.5. Effect of UV exposure and sonication on SRE and SYRA0.6,1.95  activities.  
SRE: UV exposure (●), sonication (○). SYRA0.6,1.95: UV exposure (■), sonication (□) 
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Fig. 3.6. HPLC analyses of (A) SRE (1mg/ml) and (B) SYRA0.25,0.75   before trypsin 
treatment (---) and after trypsin treatment (−). Shown are the Shown are the HPLC 
profiles obtained using a C18 column with a 25 minute of 0-70% gradient   
2-propanol in 0.1% TFA.  
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CHAPTER 4  
 
MECHANISM OF ACTION OF SRE- RLzonix COMBINATION  
 
 
Introduction  
 
 
Syringomycin E is a cyclic lipodepsinonapeptide produced by the 
phytopathogenic strains of Pseudomonas syringae pv. syringae (Takemoto, 1992).  SRE 
has inhibitory activity against fungi and yeast such as Botrytis cinerea, Geotrichum 
candidum and Rhodoturula pilimanae (Takemoto et al., 1992; Lavermicocca, et al., 
1997).  The mechanism of action of SRE is well studied.  SRE acts on yeast and plant 
plasma membranes to cause numerous cellular effects with increases in cellular K+ efflux 
and transient Ca2+ fluxes among the most prominent.  The effects are consistent with 
SRE’s ability to form ion-conducting voltage sensitive channels in membrane bilayers.  
However, ion channel formation in the native plasma membrane as the primary cause of 
growth inhibition has not yet been determined.  In addition, studies with lipid 
biosynthesis yeast mutants have revealed that sphingolipids and sterols  modulate the 
fungicidal activity of SRE (Cliften et al., 1996; Grilley et al., 1998; Stock et al., 2000).  
For instance, among the genes that promote SRE action, the SYR2 is gene required for 
sphingolipid C-4 hydroxylation, ELO2 and ELO3 are responsible for very long fatty acid 
elongation, FAH1, responsible for α-hydroxylation of the amide linked very long chain 
fatty acids, and IPT1, which encodes the enzyme that catalyzes the terminal yeast 
sphingolipid biosynthetic step (Cliften et al., 1996, Grilley et al., 1998; Stock et al., 
2000).  In addition, SMR1 (identical to ERG3), which  encodes the C-5,6 desaturase 
required for ergosterol biosynthesis (Taguchi et al., 1994) is also needed for SRE action. 
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SRE lipidic pore formation has been proposed as the mechanistic basis for SRE action on 
membranes (Malev et al., 2002). 
Rhamnolipids are produced by Pseudomonas aeruginosa and are formed by 
rhamnose linkage to fatty acids of saturated or unsaturated alkyl chain between C8 and 
C12 ( Haba et al., 2002).  Rhamnolipids possess antimicrobial activities ( Haba et al., 
2002).  They are active against zoosporic plant pathogens (Stanghellini et al, 1997) and 
other fungal species such as Fusarium solani and Penicillium funiculosum ( Haba et al., 
2002).  The mechanism of action of rhamnolipids against fungi is still unknown. 
However, Stanghellini and Miller (Stanghellini & Miller, 1997) suggested that the 
rhamnolipids inhibit the zoosporic fungi by disrupting the zoospore plasma membrane. 
Combinations of existing fungicides show some promise for use as next 
generation and more effective antifungal strategies (Rex et al., 1995).  The current work 
is part of a general study on the antifungal properties and efficacy of combined SRE and 
RL zonix formulations.  I hypothesize that SYRA the combination of SRE and RLzonix also 
inhibit fungi by mechanisms that are similar to those for SRE action.  Therefore, I studied 
the effects of SYRA on Saccharomyces cerevisiae strains deficient in various steps of 
sphingolipid and sterol biosynthesis to investigate whether the antifungal action of 
SYRA, like SRE, depends on sphingolipids and sterols.   
To further examine the basis for the fungicidal activity of SYRA, I studied the 
channel-forming properties of SRE, RLzonix , and SYRA  in lipid bilayers in comparison 
with those of SRE.  The results suggest that sphingolipids and sterols are important for 
the killing action of SYRA in a manner similar to the mechanism of action of SRE, and I 
found that SYRA and SRE have similar single-channel pore forming properties. 
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Materials and Methods 
 
 
SRE and SYRA 
 
SRE was purified from P.syringae pv.syringae strain B301D by the method of 
(Bidwai et al., 1987). P.syringae pv.syringae strain B301D was grown in non-
commercial potato dextrose casamino acids medium in 4- or 8-liter cultures as described 
by Zhang and Takemoto (1987).  The SRE was extracted from cultures using acidified 
acetone and purified using the chromatographic methods described by Bidwai et al 
(Bidwai et al., 1987).  HPLC column fractions were tested for bioactivity by applying 10 
µl aliquots on a fresh lawn of R. pilimanae on potato-dextrose agar plates, incubation at 
28oC, and observing cleared growth inhibition areas (Zhang & Takemoto, 1987).  
Commercial rhamnolipid Zonix (RLZonix) was obtained from Jeneil Biotech, Inc.  RLZonix 
is an 8.5% (wt/vol) solution of rhamnolipid analogs in water. Two forms of rhamnolipids 
are in RLZonix, R1 (C26H48O9) has the molecular formula of α-L-rhamnopyranosyl-β-
hydroxydecanoyl-β-hydroxydecanoate, and R2(C32H58O13) is 2-O-α-L-
rhamnopyranosylα-L-rhamnopyranosyl- β  hydroxydecanoate.  A formulation was 
prepared by combining SRE and RLZonix at 1:3 (wt/wt) ratios (0.25 mg SRE and 0.75 mg 
RLZonix per ml), respectively, and designated  SYRA0,25,0.75.  
 
Yeast strains and maintenance 
SRE-sensitive S. cerevisiae strains 8A-1B, W303C, and BY4741 and isogenic 
SRE-resistant and lipid biosynthesis mutant strains ∆erg3, ∆syr2, ∆ipt1, ∆elo2, ∆elo3, 
∆skn1 and ∆fah1 were described previously.  SRE-resistant strains ∆syr2 and ∆elo3 are 
single-gene disruptants isogenic to parental strains W303C and 8A-1B, respectively.  All 
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other SRE-resistant mutants are single gene disruptants isogenic to parental strain 
BY4741.  The strains were grown at 28°C and maintained at 5oC in yeast extract-peptone 
dextrose (YPD) broth or on agar medium (Hama et al., 2000). 
 
Effects on yeast growth   
Replica plating.  The effects of SRE, RLZonix , and SYRA0,25,0.75 on the growth of 
yeast strains were determined using the replica plate method as previously described 
(Hama, et al., 2000).  Freshly grown cells of yeast parental and lipid mutant strains were 
replica-plated onto YPD agar containing different concentrations of SRE, RLZonix , and 
SYRA0,25,0.75  and incubated for 2 to 3 days at 28°C.  Growth was determined by visual 
inspection of the agar plates. 
Disk diffusion assay.  The disk diffusion assay was done accordingly to the 
method described by the National Committee for Clinical Laboratory Standards 
(NCCLS) protocols for antifungal testing with modification (NCCLS, 1997,2002). 
Different  yeast parental and lipid mutant strains  were grown on YPD for 48 h at 28°C 
and 50 µl of cell suspension was transferred and spread uniformly using a cotton swab 
onto YPD agar  (Steinbach et al., 2004).  Four mm diameter sterilized paper disks were 
deposited on the surface and 10 µl of SRE (0.25 mg/ml), RLZonix (0.75 mg/ml), and 
SYRA0,25,0.75 were applied onto each disk.  The plates were incubated for 24 to 48 h and 
the zones of inhibition were measured. 
Microbroth dilution assay.  Minimal inhibitory concentrations (MICs) were 
determined by the microbroth dilution assay according to methods outlined by the 
NCCLS with modification (NCCLS, 1997, 2002).  Yeast parental and lipid mutant strains 
were grown to a final concentration of 108 CFU/ml and suspended at a final concentration 
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of 5 x105 CFU/ml.  Cell suspensions (25 µl ) were added to 25µl aliquots of twofold serial 
dilutions of SRE, RLZonix , and SYRA0,25,0.75 and YPD broth media were dispensed (100 
µl  total volume) in wells of 96-well polystyrene microtiter plates (Fisher Scientific, 
catalog no. 21-377-203).  The plates were incubated for 24 h at 28°C.  The MICs were 
determined by visual inspection of the 96-well plate. 
 
Lipid bilayer channel formation 
Lipid bilayer electrophysiological experiments were performed using 1,2-
dioleoyl-sn-glycero-3-phosphorylcholine (DOPC), (Avanti Polar Lipids) as previously 
described (Blasko et al., 1998, Malev et al., 2002).  Solutions of 0.1 M of NaCl were 
buffered with 5 mM MOPS (Sigma) to pH 6.  Bilayer lipid membranes were prepared by 
the monolayer-opposition technique (Montal & Muelle; 1972) on a 50–100 µm diameter 
aperture in the 10 µm thick Teflon film separating two (cis and trans) compartments of a 
Teflon chamber (Montal & Mueller et al., 1972; Bezrukov & Vodyanoy, 1993).  The 
membrane-forming solution was DOPC.  A pair of Ag/AgCl electrodes with agarose/2 M 
KCl bridges was used to apply transmembrane voltages and to measure single channel 
currents.  Current measurements were carried out using an Axopatch 200B amplifier 
(Axon Instruments) in the voltage clamp mode.  The data were filtered with a low-pass 8-
pole Model 9002 Bessel filter (Frequency Devices) at 1 kHz and directly recorded into 
computer memory with a sampling frequency of 5 kHz.  Data were analyzed using 
pClamp 9.2 (Axon Instruments) and Origin 7.0 (Origin Lab).  Single channel 
conductance was calculated as the mean single-channel current divided by the applied 
transmembrane voltage.  All experiments were performed at room temperature. 
SRE (5 µg/ml ) and RLZonix (4 µg/ml) were added to the aqueous phase as follows : 
 92 
1- At t=0, SRE was added to cis side compartment  
2-  At t=0, RLZonix was added to cis side compartment, then at t=10 min, SRE was 
added to the same side. 
3-  At t=0, SRE was added to the cis side compartment, then at t=10 min, RLZonix  
was added to the opposite side trans side. 
4- At t=0, RLZonix was added to the trans side, then at t=10 min, SRE was added to 
the trans side.   
 
Results 
 
Susceptibility of SRE-resistant lipid 
biosynthesis mutants 
 
The growth of S. cerevisiae sphingolipid and sterol biosynthetic mutants in the 
presence of different concentrations of SRE and SYRA0,25,0.75 was examined. On replica-
plated YPD agar medium SRE (0.75 µg/ml) and SYRA0,25,0.75 (0.5µg/ml of SRE and 1.5 
µg/ml of RLZonix) inhibited the growth of parental yeast strains (W303C, BY4741, and 
8A-1B) (Fig. 4.1) but not the lipid mutant strains ( Fig. 4.2).  SYRA0,25,0.75 was the most 
effective inhibitor against the S. cerevisiae strains (Table. 4.1, Fig. 4.2).  The MICs (of 
equivalent SRE levels in SYRA0,25,0.75)  were 2 to 4 fold lower than the SRE MICs (of 
SRE alone) (Table. 4.1) against all S. cerevisiae strains tested.  Although all of the 
mutants were less susceptible to the SRE and SYRA0,25,0.75 compared to their parental 
strains, there was some variation in the extent of resistance among the tested mutants. For 
example, the corresponding SRE-resistant isogenic mutant strains with deletions in genes 
for sphingolipid (∆syr2, ∆ipt1, and ∆skn1) or ergosterol (∆erg3) biosynthesis were less 
susceptible to inhibition by SYRA0,25,0.75 compare to the other mutants ( ∆fah1, ∆elo3, 
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and ∆elo2).  However, in the case of SRE, ∆syr2 and ∆erg3 were the most resistant 
compared to the other strains. Overall, the patterns of relative susceptibility and 
resistance of the lipid mutants to SYRA0,25,0.75 and SRE were similar.  At relatively high 
concentrations of SRE (3.9 µg/ml) and SYRA0,25,0.75 (1,95µg/ml SRE and 5,85 µg/ml 
RLZonix ) neither the wild type nor the mutants grew. 
 
Ion channel formation 
To study the influence of RLZonix on SRE interaction with the plasma membrane,  
I examined the membrane channel forming properties of SRE in the presence and 
absence of RLZonix.  The effects on ion conductance across planar lipid bilayers were 
measured.  Figure. 4.3 shows time courses of the integral macroscopic conductance of the 
bilayers doped with SRE alone and SRE with RLZonix. 
The results showed that the negative potential application drove the increase of 
the membrane conductance. Remarkably, the addition of RLZonix to both sides of the 
bilayer (cis and trans) caused a significant increase in membrane conductance indicating 
an increase in the number of pores formed by the combined mixture of SRE and RLZonix.  
However, after 40 min of the imposing voltage, the conductance decreased indicating the 
closing or disappearance of the pores.  As reported previously (Szabo et al., 2004) 
(Malev et al., 2002), SRE produced a smaller steady-state conductance and no 
subsequent decrease was observed after 40 min. No change in conductance was observed 
when RLZonix was applied alone.  In contrast to the differences in macroscopic 
conductance, the properties of the transmembrane single channels formed by SRE with or 
without RLZonix were the same (Fig. 4.3). 
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Discussion 
 
It is known that SRE interacts with membranes resulting in lipidic pore formation 
that in yeast leads to ion leakage, membrane dysfunction, and possibly other cell 
damaging effects.  It is also known that growth inhibition by SRE is modulated by 
sphingolipids and sterols (Grilley et al., 1998; Cliften et al., 1996; Stock et al., 2000; 
Hama et al., 2000) Sphingolipid and sterol biosynthetic mutants of yeast were less 
susceptible to SRE as compared to the isogenic wild type strains.  The same effect was 
observed with SYRA.  However, the presence of RLZonix rendered the wild type and the 
mutants cell more sensitive to SRE. the effect was greatest in yeast with mutations in 
either  SYR2, the gene responsible for C4 hydroxylation of sphingolipids, or  SMR1, 
which encodes the C-5, 6 desaturase required for ergosterol biosynthesis.  It is unclear 
whether the RLZonix interaction with the plasma membrane was affected by the 
sphingolipid and sterol biosynthetic mutation such as the lack of C-4 hydroxylation or 
C5, 6 desaturase as it was shown for SRE action.  However, the presence of RLZonix 
facilitated SRE binding to the plasma membrane.  Thus, SRE was more effective and it 
increased its activity. 
To further explore and understand the effect of RLZonix on SRE action, the 
transmembrane channel properties of SRE+ RLZonix were examined and compared to 
those of SRE channels.  SRE caused voltage-dependent macroscopic conductance 
increases due to the formation of ion permeable channels in the membrane bilayers. 
However, when RLZonix was added, a significant increase in the conductance level was 
observed.  This increase is mainly due to the total numbers of channels formed. I suggest 
that the observed increase in the number of channels is due most likely to the 
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enhancement and favorable binding of SRE in the presence of RLZonix.  However, after 40 
min a decrease in conductance was observed as a consequence of pore inactivation in the 
planar membrane.  This perhaps is triggered by the dissociation of SRE+ RLZonix complex 
from the plasma membrane.  The nature of interaction between SRE, RLZonix, and the 
plasma membrane, however, is not clear. One possibility is that the penetration of RLZonix 
into the plasma membrane (in which the hydrophobic portion interacts with lipids and the 
negatively charged polar head points outward in a carpet-like manner (Oren & Shai, 
1998) attracts more SRE binding to the membrane to give an increase in number of 
channels (Fig. 4.4).  It is important to mention that the nature of the membrane plays an 
important role in how RLZonix binds and inserts into the membrane (Aranda, et al., 2007). 
Aranda, et al., (2007) suggested that a high presence of cholesterol in the membrane 
rendered the binding of diRL more difficult; however, the presence of 
phosphatidylethanolamine enhanced its binding and partitioning into the membrane.  
Another possibility is that SRE interacts with the plasma membrane with a barrel-stave  
mechanism as described by Oren et al. (1998) for linear amphipathic peptides.  The 
positive charge of the SRE polar head and pore formation results in a decrease in the 
motional order of the lipids and as a consequence, RLZonix binding and insertion into the 
membrane is enhanced (Aranda et al., 2007) with an increase in the number of channels.  
In summary, the present study suggests that SYRA inhibits yeast by the same 
mechanism as does SRE by itself.  Its antifungal action is promoted by sphingolipids and 
sterols of the plasma membrane and involves pore formation.  The results also provide an 
explanation for the antifungal synergy between SRE and RLZonix.  The addition of RLZonix 
results in an increase in the number of membrane channels formed by SRE. 
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Table. 4.1 Antimicrobial activities of SRE and SYRA against yeast lipid  
              biosynthetic mutants. 
Organisms Zone of inhibition 
(mm) 
 
MIC (µg/ml) 
Saccharomyces 
cerevisiae 
SRE SYRA SRE SYRA  
(SRE/ RLZonix ) 
W303C 14 25 0.97 0.48/1.44 
∆syr2 10 7 3.9 1.95/5.85. 
∆elo3 14 19 1.95 0.97/2.91 
     
BY4741 13 24 0.97 0.48/1.44 
∆ipt1 12 17 1.95 1.95/5.85 
∆fah1 12 22 1.95 0.97/2.91 
∆elo2 12 22 1.95 0.97/2.91 
∆skn1 12 22 1.95 0.97/2.91 
     
∆8A-1B 15 24 0.97 0.48/1.44 
∆smr1 10 8 3.9 1.95/5.85 
MICs values were obtained from triplicate determinations 
The zone of inhibition: The error was ± 2 mm, as determined from triplicate 
determinations 
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                      Control 
 
 
               SRE 0.75µg/ml 
 
 
               SYRA 0.5µg/ml, 1.5µg/ml 
Fig. 4.1 .Effect of SRE and SYRA on growth of yeast lipid biosynthetic mutants. 
Sphingolipid and ergosterol biosynthesis mutant and parental strains were replica plated 
onto YPD agar with or without: SRE (0.75µg/ml) or SYRA (0.5µg/ml SRE, 1.5µg/ml 
RL) the plates were incubated at 28°C for 48 h. 
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 SRE SYRA0,25,0.75   
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 . SRE and SYRA0,25,0.75  inhibition against yeast lipid biosynthetic mutants.  Ten µl 
of SRE (0.25mg/ml) and SYRA0,25,0.75  were applied on the disks. The plates were incubated 
for 48 h. RLZonix showed no inhibition. 
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FIG.4.3.  Time course of  ion conductance of  bilayers doped with A)- SRE, B)- SRE and 
RL applied to Cis side. C)- SRE applied to  cis side and RL to trans side  , recorded at the 
applied voltage of –50 mV 
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Fig. 4.4. A cartoon illustrating on the mechanism of SRE and RL combination and 
membrane pore formation.  Red symbol represents RL and blue symbol represents SRE.  
Left: A- the RL interacted with the plasma membrane with their hydrophobic embedded 
in the membrane and hydrophilic portion on the surface. B- the binding of RL attracted 
more SRE to the surface of the plasma membrane. Right: A-the syringomycin interacts 
with the plasma membrane. B- The binding of SRE resulted in channel formation and a 
decrease in the motional order of the lipids as a consequence, RLZonix binding and 
insertion into the membrane is enhanced with an increase in the number of channels.  
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CHAPTER 5 
 
MECHANISMS OF YEAST GROWTH INHIBITION  
 
BY SYRINGOPEPTINS 
 
 
Introduction 
 
 
In addition to well-characterized cyclic lipodepsinonapeptides, Pseudomonas 
syringae pv. syringae produces larger cyclic lipodepsipeptides known as the 
syringopeptins (SPs). These compounds are composed of 22 or 25 amino acids (SP22 and 
SP25, respectively) with an octadepsipeptide ring structure and a 3-hydroxy fatty acyl 
chain.  Isoforms of SP22 and SP25 possessing fatty acyl chains composed of ten and 
twelve carbons are designated A and B homologs, respectively.  The SPs are phytotoxic, 
and they have antimicrobial activities against Gram-positive bacteria (Lavermicocca et 
al., 1992; Grgurina et al., 2005, Chapter 6).  They are also antifungal although typically 
less potent in this regard than the cyclic lipodepsinonapeptides (Iacobellis et al. 1992; 
Lavermicocca et al., 1997; Grgurina et al., 2005).  Nevertheless, SP22 analogs show 
strong inhibitory activities against certain fungal yeasts including the pathogen Candida 
albicans (Grgurina et al., 2005). 
The mechanisms of action of the cyclic lipodepsinonapeptides, particularly 
syringomycin E (SRE), are well studied.  SRE acts on yeast and plant plasma membranes 
to cause numerous cellular effects with increases in cellular K+ efflux and transient Ca2+ 
fluxes among the most prominent.  The effects are consistent with SRE’s ability to form 
ion-conducting voltage sensitive channels in membrane bilayers.  However, ion channel 
formation in the native plasma membrane as the primary cause of growth inhibition has 
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not yet been determined.  In addition, studies with yeast have revealed that sphingolipids 
and sterols (lipids that occur predominantly in the plasma membrane) modulate the 
fungicidal activity of SRE (Cliften et al., 1996; Grilley et al., 1998; Stock et al., 2000).  
SRE lipidic pore formation has been proposed as the mechanistic basis for SRE action on 
membranes (Malev et al., 2002).  Less is known of the mechanisms of action of the SPs.  
A few studies have shown that the SPs are capable of forming ion conducting membrane 
channels (Hutchison & Gross, 1997; Dalla Serra et al., 1999; Agner et al., 2000).  In lipid 
bilayers and erythrocytes, SP22A channels do not thermally inactivate as do SRE 
channels – a phenomenon related to SP22A’s greater effectiveness in ordering membrane 
lipids (Szabo et al., 2004).  In plant systems, SPs have been shown to cause electrolyte 
leakage in leaf tissues (Iacobellis 1992; Lavermicocca et al., 1997), to increase the 
permeability of tonoplasts (Carpaneto et al., 2002), close stomata (Di Giorgio et al., 
1996) and modify H+ fluxes across mitochondria and plasma membranes (Di Giorgio et 
al., 1994;1996).  Finally, SPs interact with bacterial cell surface teichoic acids (Chapter 
6Bensaci), but the mechanism of interaction with bacterial membranes is still unknown.  
Despite recognition that the SPs have antifungal activities, there have been no published 
studies on the mechanisms of action of SPs against yeasts or other fungi. 
In this study, we address the mechanisms of action of SPs against yeast.  We show 
that the physiological responses of yeast to the SPs and the membrane lipid requirements 
for fungicidal action resemble those of SRE.  This is so despite the large structural 
differences between the SPs and SRE molecules.  To examine the basis for the fungicidal 
activity of SPs, we studied the channel-forming properties of the SPs in lipid bilayers in 
comparison with those of SRE. We found that SP22A and SP25A produce higher 
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macroscopic conductance than SRE but, surprisingly, have similar single-channel 
properties. 
 
Materials and methods 
 
Yeast strains and maintenance 
Saccharomyces cerevisiae SRE-sensitive strains KZ1-1C, 8A-1B, W303C, and 
BY4741 and SRE-resistant and lipid biosynthesis mutant strains ∆erg3, ∆syr2, ∆ipt1, 
∆elo2, ∆elo3 and ∆fah1 were described previously (Taguchi et al., 1994, Hama et al., 
2000, Stock et al., 2000).  SRE-resistant strains ∆erg3 (formerly ∆syr1, (Taguchi et al., 
1994)) and ∆fah1 are single-gene disruptants isogenic to parental strains 8A-1B and 
BY4741, respectively.  All other SRE-resistant mutants are single gene disruptants 
isogenic to parental strain W303C.  The strains were grown (28°C) and maintained (5oC) 
in yeast extract-peptone dextrose (YPD) broth or on agar medium (Hama et al., 2000). 
 
Purification of SRE, SP22A and SP25A 
SRE was purified from Pseudomonas syringae pv. syringae strains B301D or M1 
by previously described methods of (Bidwai et al., 1987; Adetuyi et al., 1995).  SP22A 
and SP25A were purified from extracts of strains P. syringae pv. syringae B301D and 
M1 respectively, using methods described earlier (Chapter 6). 
 
Effects on yeast growth 
The effects of SP22A, SP25A and SRE on the growth of yeast strains were 
determined using two methods.  A replica plate method was used as previously described 
(Hama et al., 2000).  Freshly grown cells of yeast parental and lipid mutant strains were 
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replica-plated onto YPD agar medium containing different concentrations (between 0.61 
and 2.06 uM) of SRE, SP22A, and SP25A and incubated for 2 to 3 days at 28°C. Growth 
was determined by visual inspection of the agar plates.  For measuring effects on growth 
in liquid batch cultures, parental yeast strain KZ1-1C was first grown in YPD broth 
medium at 28°C in 125 mL capacity Erlenmeyer flasks with rotary shaking for 48h to a 
density of ~8 x 108 cells ml-1. The cells were centrifuged and resuspended in YPD broth 
medium to give 2.4 ×107 cells ml-1 and SRE, SP22A or SP25A were added at designated 
concentrations (between 0.81 and 9.33 uM). The suspensions were incubated with rotary 
shaking at 28°C and samples removed hourly for direct cell counts. The number of cells 
was counted using a hemocytometer and light microscope and generation times 
determined from calculated specific growth rate constants. 
 
K+ efflux  
Whole cell K+ efflux rates were determined as changes in extracellular K+ 
concentrations. Yeast strain KZ1-1C was grown in YPD broth medium with rotary 
shaking at 28oC to a density of 108 cells ml-1. Cells were suspended in 2 mM Tris/MES 
buffer, pH6.5, and 0.1M-glucose with or without SRE, SP22A or SP25A (at 
concentrations of 1, 10 or 100 µM) to A600 nm of 1 in 125 ml capacity Erlenmeyer flasks 
with rotary shaking (200 rpm) at 28oC (Takemoto et al., 1991).  At 5 min after 
suspension, 1 ml samples were withdrawn, centrifuged in an Eppendorf microcentrifuge 
for 30 sec, and the supernatant fractions were recovered.  K+ concentrations were 
determined by atomic absorption spectroscopy (AA/AE spectrophotometer 457, 
Instrumentation Laboratories). 
Ca2+ uptake 
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The net cellular uptake of 45Ca2+ was measured using strain KZ1-1C as described 
previously (Takemoto et al., 1991).  Cells were grown in YPD broth medium to a density 
of 1 X 107 cells ml-1, harvested by centrifugation, and then suspended in YPD broth 
medium to a density of 4 x 107 cells ml-1). Ten mL aliquots were dispensed in 125 ml 
capacity Erlenmeyer flasks with radioactive 45CaCl2 (Amersham Radiochemicals) and 
incubated with rotary shaking (200 rpm) at 28oC.  The specific radioactivity of 45Ca2+ 
was adjusted to 4mCi (148MBq) per mmole of CaCl2 (Takemoto et al., 1991). SRE, 
SP22A or SP25A were added 5 min following addition of 45CaCl2.  At designated times, 
cell samples (200 µl) were collected on glass fiber filters (0.45 µM pore size), the filters 
were quickly washed twice with ice-cold water, and the radioactivity on the filters 
determined using a liquid scintillation counter. 
 
Channel formation in lipid bilayers  
Lipid bilayer electrophysiological experiments were performed using 1,2-
dioleoyl-sn-glycero-3-phosphorylcholine (DOPC) (Avanti Polar Lipids) as previously 
described (Blasko et al., 1998; Malev et al., 2002). Solutions of 0.1 M NaCl were 
buffered with 5 mM MOPS (Sigma) to pH 6.  Bilayer lipid membranes were prepared by 
the monolayer-opposition technique (Montal & Mueller, 1972) on a 50–100 µm diameter 
aperture in the 10 µm thick Teflon film separating two (cis and trans) compartments of a 
Teflon chamber. SP22A, SP25A, or SRE were added to the aqueous phase of the cis-side 
compartment.  A pair of Ag/AgCl electrodes with agarose/2 M KCl bridges was used to 
apply transmembrane voltages and to measure single channel currents.  All experiments 
were performed at room temperature. Current measurements were carried out using an 
Axopatch 200B amplifier (Axon Instruments) in the voltage clamp mode.  The data were 
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filtered with a low-pass 8-pole Model 9002 Bessel filter (Frequency Devices) at 1 kHz 
and directly recorded into computer memory with a sampling frequency of 5 kHz.  Data 
were analyzed using pClamp 9.2 (Axon Instruments) and Origin 7.0 (Origin Lab). 
Current transition histograms were generated for each tested voltage. Histogram peaks 
were fitted with the normal distribution function. Single channel conductance was 
calculated as the mean single-channel current divided by the applied transmembrane 
voltage. 
 
Results 
 
Yeast growth inhibition by SP22A and SP25A  
The growth of  S.  cerevisiae strain KZ1-1C in batch cultures with YPD broth 
medium was completely inhibited by SP22A and SP25A at concentrations of 4.66 µM 
and 8.24 µM, respectively (Table 5. 1).  In contrast, SRE gave complete inhibition at  
0.81 µM.  In all cases, growth did not resume after 48h indicating that inhibition was 
fungicidal. 
 
Susceptibility of SRE-resistant lipid mutants 
On replica-plated YPD agar medium SP22A and SP25A inhibited the growth of 
parental yeast strains (W303C, BY4741, and 8A-1B) at 1.16 µM and 2.06 µM, 
respectively (Fig. 5.1). Corresponding SRE-resistant isogenic mutant strains with 
deletions in genes for sphingolipid (∆syr2, ∆ipt1, ∆elo2 and ∆elo3) or ergosterol (∆erg3) 
biosynthesis were less susceptible to inhibition by SP22A and SP25A at these respective 
concentrations (Fig. 5. 1). In contrast, sphingolipid α−hydroxylase mutant ∆fah1 was 
more susceptible to SP22A than to SRE or SP25A.  This mutant strain was nevertheless 
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resistant to SP22A concentrations below 1 µM that were still inhibitory to isogenic strain 
BY4741 (data not shown).  Overall, the patterns of relative susceptibility and resistance 
of the lipid mutants to SP22A and SP25A were similar to those shown previously for 
SRE (Cliften et al., 1996; Hama et al., 2000; Stock et al., 2000). 
 
Effects on K+ efflux 
As previously observed for SRE (Takemoto et al., 1991), SP22A and SP25A 
stimulated K+ efflux from cells of strain KZ1-1C (Fig. 5.2).  Higher concentrations of 
SP22A and SP25A were required to give the effect as compared to SRE.   SRE 
stimulated K+ efflux as low as 1 µM.  But, 10 and 100 µM of SP22A and SP25A, 
respectively, were required to achieve similar degrees of K+ efflux. 
 
Effects on Ca2+ uptake 
As previously observed for SRE (Takemoto et al., 1991), SP22A and SP25A 
stimulated Ca2+ uptake by strain KZ1-1C cells (Fig. 5. 3).  As with K+ efflux (Fig. 5. 2), 
higher concentrations of SP22A and SP25A, as compared to SRE, were required to 
produce the effect.  Ca2+ uptake was observed within 15 min after 5 µM SRE addition.  
But, 40 µM and 120 µΜ were the minimal concentrations of SP22A and SP25A, 
respectively, required for observing Ca2+ uptake.  At these concentrations, Ca2+ uptake 
was not evident until about 20 min and 30 min after addition of SP22A and SP25A, 
respectively.  
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Channel formation in lipid bilayers 
To examine the membrane channels properties of SRE and SPs, their effects on 
ion conductance across planar lipid bilayers were measured. Figure.5. 4-A shows time 
courses of the integral conductance of the bilayers doped with SP22A, SP25A, and SRE. 
In all three cases, negative potential application drove the increase of the membrane 
conductance after 5 min delay followed by stable conductance levels for 10 minutes. 
Positive voltages produced membrane conductance decreases (not shown), indicating 
closing of the pores. SP22A produced slightly higher conductance than SP25A (10 
individual observations).  SRE produced smaller steady-state conductance levels, even at 
concentrations of SRE that were higher than those of the SPs (17 µM of SRE vs. 0.1 µM 
of SP22A and 0.11 µM of SP25A). 
 The single-channel recordings with all three lipodepsipeptides were similar (Fig. 
5.4).  In all cases, two types of single-channel conductance fluctuations were observed, 
small and large, differing in the levels of conductance 5 to 6 fold. The dwell times of the 
large channels were longer than the small ones. The values of the single-channel 
conductance for the small channels over the range of ±200 mV were similar for all three 
lipodepsipeptides (Fig. 5.4-C). Thus, the properties of the transmembrane channels, 
formed by SRE, SP22A, and SP25A were essentially the same. 
 
Discussion 
 
 
Despite the structural differences between SRE, SP22A, and SP25A, all three 
lipodepsipeptides displayed similar physiological and model membrane-permeabilyzing 
activities.  They stimulated Ca2+ uptake and K+ efflux by yeast cells. SRE, however, was  
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active at lower concentrations compared to the SPs, which parallels its relatively higher 
fungicidal activities.  As in the case of SRE, it is not yet known how the SPs cause 
changes in fluxes.  However, it is likely that they both form pores in the plasma 
membrane as a key step in their action that leads to ion leakage, membrane dysfunction, 
and possibly other cell-damaging effects. It is also shown that growth inhibition by the 
SPs is modulated by sphingolipids and sterols, which also is the case with inhibition by 
SRE (Cliften et al., 1996; Hama et al., 2000).  Sphingolipids and sterol biosynthetic 
mutants of yeast were less susceptible to SP22A and SP25A as compared to the isogenic 
wild type strains.  By analogy to SRE action, it is suggested that the SPs also impart 
fungicidal activities by forming lipidic pores that are influenced by specific sphingolipids 
and sterols (Malev et al., 2002; Takemoto, 2003; Kaulin et al., 2005).  
To further explore their resemblance, the transmembrane channel properties of 
SP22A and SP25A were examined and compared to those of SRE channels.  SP22A and 
SP25A caused voltage-dependent macroscopic conductance increase due to the formation 
of ion-permeable channels in the membrane bilayers. Both SPs were ~150 times more 
effective in channel formation than SRE.  At the same time, despite large structural 
differences, the properties of single channel formed by all three cyclic lipodepsipeptides 
were very close (Fig. 4.5).  Thus, the differences in macroscopic transmembrane 
conductance levels were mostly due to differences in the total numbers of channels 
formed by SRE vs. SP22A and SP25A.  We suggest that the observed differences in the 
membrane activity of SPs and SRE most likely stem from the structural differences in 
their molecules, and, subsequently, from differences in interaction with the DOPC 
bilayers.  As opposed to the SPs, SRE lacks a hydrophobic peptide domain. SP22 and 
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SP25 have hydrophobic peptide domains of fourteen and seventeen amino acids, 
respectively (Ballio et al., 1991).  As a consequence, the SPs will interact more favorably 
with the lipid bilayer than will SRE.  It is not known precisely how the SPs and SRE 
interact with membrane lipids to form channels (Malev et al., 2002).  However, the 
electrostatic and hydrophobic interactions between SP22A and the lipid membrane are 
known to increase lipid order as a prelude to stable pore formation (Szabo et al., 2004).  
In addition, it was shown that unlike SRE, the SP22A pore was not thermally inactivated 
suggesting a higher degree of affinity between SP22A and membrane lipids.  
In summary, the present study suggests that although different in fungicidal 
potencies, SRE and the two SPs kill yeast cells by the same mechanism, involving lipid-
dependent membrane pore formation as a crucial step.  Like SRE, the action of the SPs 
against yeast is promoted by sphingolipids and sterols of the plasma membrane.  Our 
observations also show that the structures of pores formed by SRE and the SPs in 
membranes are very similar despite large structural differences between these molecules.  
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TABLE. 5.1.  Effects of SRE, SP22A, and SP25A on batch culture growth of S. 
cerevisiae strain KZ-IC*   
 
Additions to 
medium (µM) 
+Generation time (hr) 
 
None  
 
5.33 
 
SRE   
0.81 
 
 
∞ 
 
SP22A 
2.33 
4.66 
9.33 
 
 
8.66 
∞ 
∞ 
 
SP25A 
2.06 
4.12 
8.24 
 
 
6.3 
8.66 
∞ 
* Growth was determined by microscopic direct cell counts during exponential growth in 
YPD broth medium. 
+
 Calculated as 0.693 divided by the specific growth rate (cell doubling hr-1) during 
exponential growth. 
∞ = infinite  
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FIG. 5.1. Effect of SRE and SPs on growth of yeast lipid biosynthetic mutants. 
Sphingolipid and ergosterol biosynthesis mutant and parental strains were replica plated 
onto YPD agar with or without: SP25A (2.06µM), SP22A (1.16µM), or SRE (0.61µM). 
The plates were incubated at 28°C for 48 h.  
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FIG. 5.2. Effects of SRE (blank bars), SP22A (grey bars) and SP25A (striped bars) on 
K+ efflux by yeast strain KZ1-1C cells growing in YPD medium.  The cells were 
exposed to designated concentrations of SRE, SP22A or SP25A and extracellular K+ 
concentrations measured . The same results were obtained from three separate 
experiments.  Results from a single experiment are presented. Control efflux was 
similar to SP25A at 1µM.  
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FIG. 5.3.  Effects of SRE, SP22A and SP25A on 45Ca2+  uptake by strain KZ1-1C 
cell suspensions. SRE and SPs were added 5 min following addition of 45CaCl2.  
SP22A concentrations were 10 (♦). 40 (■); SP25A (dashed lines) concentrations 
were 10 (♦) , 40 (○) , and 120 (∆) µM; SRE concentration was 5µM (•).  Total CaCl2 
concentration was 50 µM.  The same results were obtained from two separate 
experiments. Results from a single experiment are presented.  
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FIG. 5.4.  (A) Time courses of the ion conductance of the bilayers doped with SRE, SP22A, 
and SP25A, recorded at the applied voltage of –100 mV. (B) Records of conductance 
fluctuations at –150 mV transmembrane potential of SRE, SP22A, and SP25A-modifuied 
bilayers. (C) conductance-voltage curves for SRE, SP22A and SP25A small channels 
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CHAPTER 6 
 
SYRINGOPEPTIN SP25A INHIBITION OF GRAM-POSITIVE  
BACTERIA AND ROLE OF TEICHOIC ACID  
D-ALANYLATION 
 
 
Introduction 
 
 
The syringopeptins are secondary metabolites produced by many strains of the 
plant-associated bacterium Pseudomonas syringae (Ballio et al., 1991; Bender et al., 
1999). They are cyclic lipodepsipeptides, with their peptide portions containing either 22 
[syringopeptins (SP)22] or 25 (SP25) amino acids that are predominantly hydrophobic 
and largely of the d configuration (Ballio et al., 1991; Isogai et al., 1995) (Fig. 6.1). A 
common N-terminus dehydroaminobutyric acid (Dhb) is amide linked to a 3-
hydroxylated acyl chain containing 10 or 12 carbons to give A and B homologs, 
respectively. The C-terminus carboxyl group is ester linked to a Thr hydroxyl to form an 
eight-membered amino acid lactone ring with a net cationic charge. SP25 homologs, 
SP25A and SP25B, are produced by strains of P. syringae pv. syringae isolated from 
millet (strain B359; Ballio et al., 1991), citrus (strain B427; Ballio et al., 1991), and 
wheat (strain M1; Adetuyi et al., 1995), and by the wheat pathogen P. syringae pv. 
atrofaciens (Vassilev et al., 1996). Variants differing in the C-terminal residue (Phe vs. 
Tyr) are produced by a laurel-infecting P. syringae strain (Scaloni et al., 1997). SP22 A 
and B homologs are produced by the pear isolate P. syringae pv. syringae strain B301 
(Ballio et al., 1991), and variants are produced by P. syringae pv. syringae isolates from 
sugar cane [SP(SC; Isogai et al., 1995)], bean (SPPhv; Grgurina et al., 2002), and apple 
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(SP508; Grgurina et al., 2005). All syringopeptin-producing P. syringae strains produce 
one type of syringopeptin together with a smaller, nine amino acid-containing cyclic 
lipodepsipeptide – either syringomycin, syringotoxin, syringostatin, or pseudomycin 
(Bender et al., 1999; Takemoto et al., 2003). The syringopeptins are phytotoxic and also 
antimicrobial. In plant systems, they perturb mitochondria and protoplasts of tobacco 
leaves (Iacobellis et al., 1992; Hutchison & Gross, 1997) and form ion channels in sugar 
beet vacuoles (Carpaneto et al., 2002). They are also antifungal (Iacobellis et al., 1992; 
Lavermicocca et al., 1997), particularly when combined with cell wall-degrading 
enzymes (Fogliano et al., 2002). SP22A and SP508A have antibacterial activities against 
several Gram-positive bacteria such as Bacillus megaterium, Staphylococcus aureus, and 
Mycobacterium smegmatis but not against Gram-negative bacteria (Lavermicocca et al., 
1997; Grgurina et al., 2005). In contrast, the antibacterial spectrum for SP25A is less well 
known, although it is reported to inhibit B. megaterium and to inhibit Micrococcus luteus 
marginally (Lavermicocca et al., 1997). The molecular basis for the inhibitory specificity 
of syringopeptins against Gram-positive bacteria is not known. The most probable 
physiological targets of the syringopeptins are membranes, and lipid bilayer studies 
suggest that the inhibitory mechanism of action involves formation of membrane pores 
(Hutchison & Gross, 1997; Dalla Serra et al., 1999). 
Teichoic acids are major cell surface components of Gram-positive bacteria that 
confer high densities of negative charges (phosphate groups) on the cell envelope surface. 
Such anionic sites might serve as initial ionic interaction sites for the cationic 'head 
groups' of the syringopeptins. The charge densities of peptidoglycan-linked wall teichoic 
acids and membrane-linked lipoteichoic acids are modulated by esterification with d-
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alanine. The enzymes that catalyze and regulate teichoic acid d-alanylation are encoded 
by five genes of the dlt operon (Perego et al., 1995). Genes dltA and dltC encode a d-
alanine-d-alanyl carrier protein ligase and d-alanyl carrier protein, respectively. Both dltB 
and dltD encoded proteins facilitate the transport of activated d-alanine across the 
membrane for incorporation into lipoteichoic acid. The function of the fifth gene of the B. 
subtilis dlt operon, dltE, remains unknown and defects in dltE do not lead to impairment 
of d-alanylation. d-alanine moieties of lipoteichoic acid serve as precursors for d-
alanylation of wall-linked teichoic acids (Haas et al., 1984). Studies with dlt mutants 
reveal that teichoic acid d-alanylation is not essential for viability (Perego et al., 1995), 
but the process influences susceptibility to lysis (Peschel et al., 1999), acid (Boyd et al., 
2000), and antimicrobial peptides (Peschel et al., 2000; Kristian et al., 2005). 
In the present study, the antimicrobial spectrum of SP25A and it is shown that it 
specifically inhibits Gram-positive bacteria is explored further. This includes B. 
megaterium, which was previously shown to be sensitive to this syringopeptin (Iacobellis 
et al., 1992; Lavermicocca et al., 1997). Data are reported that reveal a role for d-
alanylation of teichoic acids in modulating the susceptibility of B. subtilis to SP25A and 
other syringopeptins. This is consistent with the cationic character of the cyclic peptide 
portion of SP25A, and it provides an explanation for its higher degree of specificity for 
Gram-positive bacteria. 
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Materials and Methods 
 
Syringopeptin purification 
SP25A, SP22A, and SP508A were purified from cultures of P. syringae pv. 
syringae strains M1 (Adetuyi et al., 1995), B301D (DeVay et al., 1968) and 508 
(Grgurina et al., 2005), respectively, following previously described methods (Ballio et 
al., 1991). Cultures were extracted with acidified acetone (0.4% HCl), and extracts were 
chromatographed on Amberlite XAD-2 (Bidwai et al., 1987). Final purification was 
achieved by preparative HPLC using a Varian 5000 system and an Alltech reverse-phase 
C18 silica column (Bidwai et al., 1987). For growth inhibition studies, dry and purified 
syringopeptins were each gravimetrically weighed, mixed in 0.001N HCl at a 
concentration of 10 mg mL−1 (4.6, 4.5, and 4.1 mM for SP22A, SP508A, and SP25A, 
respectively), and diluted accordingly with distilled water before use. 
 
Organisms and culture conditions 
The following organisms were obtained from the American Type Culture 
Collection (Manassas, VA): M. smegmatis ATCC 14468, Staphylococcus aureus ATCC 
6538, B. megaterium ATCC 14381, B. subtilis ATCC 1965, Alcaligenes faecalis ATCC 
8750, Escherichia coli ATCC 25922, Proteus vulgaris ATCC 13315, Pseudomonas 
aeruginosa ATCC 15442, Salmonella enterica (serovar typhimurium) ATCC 14028, 
Serratia marcescens ATCC 8100, and Citrobacter freundii ATCC 8090.  Listeria 
monocytogenes ATCC 82302and a laboratory strain of Listeria innocua were obtained 
from B. Weimer (Department of Nutrition and Food Sciences, Utah State University). 
Streptococcus agalactiae and Streptococcus pyogenes strains were obtained from the 
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Department of Biology Culture Collection, Utah State University. Mycobacterium 
smegmatis was grown at 37°C in Middlebrook 7H9 broth supplemented with 0.2% 
glycerol and 10% Middlebrook oleic acid-albumin-dextrose-catalase enrichment. 
Staphylococcus aureus was grown at 37°C in Mueller–Hinton medium (Difco), and B. 
megaterium and B. subtilis were grown in Luria–Bertani (LB) medium (Sambrook et al., 
1989) at 37°C. Listeria monocytogenes, and L. innocua were grown on brain heart 
infusion medium (Difco) at 37°C. Alcaligenes faecalis, E. coli, Proteus vulgaris, 
Pseudomonas aeruginosa, Salmonella enterica serovar typhimurium, Serratia 
marcescens, and C. freundii were grown on LB medium at 37°C. Streptococcus 
agalactiae and Streptococcus pyogenes were cultured on blood agar medium as described 
by Jasir et al. (2003).  Bacillus subtilis teichoic acid d-alanylation mutant strains and 
wild-type JH642 (trpC2, phe-1) (Perego et al., 1995) were obtained from Z. Pragai 
(University of Newcastle Upon Tyne).  The mutant strains were deleted in dltB and dltD 
by insertional mutagenesis with integrative vectors pDLT72 (derived from pJM103) and 
pDLT74A (derived from JM105A), respectively. Both mutants are deficient in d-alanine 
esterification of lipoteichoic acids and wall teichoic acids (Perego et al., 1995). A third 
dlt operon mutant strain disrupted by pDLT76 (derived from pDLT74A) and with a 
truncated dltD gene and completely defective dltE still incorporates d-alanine into 
lipoteichoic acid and wall teichoic acids at wild-type levels (Perego et al., 1995). Wild-
type strain JH642 was grown in LB medium, and the dlt mutant strains were grown in LB 
medium in the presence of 5 µg mL−1 chloramphenicol, 2 µg mL−1 kanamaycin, and 
1 µg mL−1 erythromycin (Perego et al., 1995). 
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Effects of SP25A on batch culture  
growth of B. subtilis 
 
Bacillus subtilis strains ATCC 1965, JH642 (trpC2, phe-1), pDLT72, and 
pDLT74A were each initially grown in 25 mL nutrient broth in 125 mL capacity 
Erlenmeyer flasks with gyratory shaking (200 r.p.m.) in a New Brunswick G26 incubator 
shaker for 24 h at 37°C. Ten microlitres of each of the cultures were transferred into 
100 mL of fresh nutrient broth medium in 250 mL capacity Erlenmeyer flasks containing 
0 (control), 5, or 10 µg mL−1 of SP25A. The flasks were incubated at 37°C with gyratory 
shaking in a New Brunswick G76 water bath incubator (speed setting at 6). Cell 
turbidities at designated times were measured at an absorbance wavelength of 660 nm 
with a Shimadzu UV1201 spectrophotometer using 1 cm path length cuvettes. 
 
Determination of minimal inhibitory  
concentration (MIC) values 
 
The Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS)-
approved standard reference methods for microbroth dilution susceptibility assays were 
performed to obtain MIC values (NCCLS, 1993, 2003). Bacteria, except for M. 
smegmatis and Streptococcus agalactiae and Streptococcus pyogenes, were grown to a 
final concentration of 108 CFU mL−1 and suspended to a final concentration of 5 × 
105 CFU mL−1. Cell suspensions (25–50 µL) and 10 µL aliquots of twofold dilutions of 
SP25A were deposited in wells of 96-well polystyrene plates. The plates were incubated 
at 37°C for 16–20 h. Mycobacterium smegmatis cells were grown to a density of 1.0 
McFarland unit (c. 3 × 108 CFU mL−1; Liu & Nikaido, 1999), and Streptococcus 
agalactiae and Streptococcus pyogenes colonies grown on blood agar plates were 
suspended to 0.5 McFarland units (c. 1.5 × 108 CFU mL−1) in saline (Jasir et al., 2003). 
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Inocula were diluted to 5 × 104 CFU mL−1, the cells were dispensed, and twofold dilution 
series of SP25A (initial concentration 1.0 mg mL−1) were applied to 96-well polystyrene 
plates. MICs were determined after 48-h incubation at 37°C. Minimum bacteriocidal 
concentrations were determined as described by Perry et al. (1999). After MIC 
determinations, 100 µL aliquots were removed from each micrototiter plate well and 
spread-plated on appropriate agar medium. All plates were incubated at the optimal 
temperature for each organism and growing colonies were counted after 24–48 h. The 
minimal bacteriocidal concentration values were determined as the lowest concentrations 
of SP25A that yielded a >99.9% killing of the organism. Half-maximal inhibitory 
concentration (IC50) values were determined as the SP25A concentration yielding 50% 
killing. 
 
Determination of disk diffusion zone  
of inhibition (ZI) diameters 
 
Disk diffusion assays were performed according to CLSI-approved standard 
reference methods (NCCLS, 1993) with modification. Bacteria were grown in 
appropriate media for 24–48 h. The culture densities were adjusted to 0.5 McFarland 
units, and cultures were spread on agar plate medium surfaces. Sterilized paper disks 
(0.5 cm diameter) were placed on the inoculated agar medium surfaces. Ten microlitres 
aliquots of SP25A solutions were applied to the disks , and the plates were incubated for 
16–24 h at optimal temperature (37 or 28°C) before examination and measurement of the 
diameters of the cleared ZIs. To examine pH effects on syringopeptin activities using disk 
diffusion assays, B. subtilis strains JH642 (trpC2, phe-1), dltB, dltD, and dltE mutant 
strains were spread-plated onto surfaces of LB agar medium adjusted to pHs 7.0, 9.0, or 
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5.8, syringopeptins SP25A, SP22A, or SP508A applied to disks as described above, and 
the LB agar medium plates incubated at 37°C for 16–24 h. 
 
Results and Discussion 
 
Inhibition of bacteria by SP25A 
Previous studies by Lavermicocca et al. (1997) showed that SP25A inhibited the 
growth of B. megaterium but not of several Gram-negative bacteria. In the present study, 
the inhibitory effects of SP25A against additional Gram-positive bacteria were examined, 
and its effects against Gram-negative bacteria were re-evaluated (Table. 6.1). MICs 
ranged between 1.95 and 7.8 µg mL−1 for all Gram-positive bacteria tested. The 
inhibition by SP25A was bacteriocidal as the minimal bacteriocidal concentrations were 
identical to the MICs. IC50 values were twofold lower than the corresponding MIC 
values. In contrast and consistent with the previous observations (Lavermicocca et al., 
1997), none of the Gram-negative bacterial species tested were inhibited by SP25A 
(Table. 6.1). 
 
Effects of SP25A on B. subtilis teichoic  
acid d-alanylation mutants 
 
The basis for SP25A's specificity against Gram-positive bacteria was studied 
using B. subtilis teichoic acid d-alanylation dlt mutants. SP25A at 5 µg mL−1 inhibited dlt 
operon wild-type B. subtilis strains JH642 (trpC2, phe-1) to varying degrees when grown 
with aeration at 37°C in nutrient broth (Fig.6.2). Strain JH642 grew slowly with 
5 µg mL−1 SP25A with a generation time of 6.97±0.07 h compared with a generation time 
of 1.58±0.41 h when grown with no added SP25A. In contrast, d-alanylation mutant 
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strains pDLT74A (dltB deletion) and pDLT72 (dltD deletion) (both constructed in strain 
JH642) were completely inhibited by 5 µg mL−1 SP25A. Therefore, the lack of d-
alanylation of teichoic acids led to a higher degree of sensitivity to SP25A. SP25A at 
10 µg mL−1 completely inhibited the growth of these strains as well as B. subtilis strain 
ATCC 1965. The higher sensitivities of the dltB and dltD mutants were also evident from 
microbroth dilution susceptibility and disk diffusion assays. Both mutants showed 
approximately fourfold lesser MIC values (0.98 µg mL−1) and twofold larger ZI 
diameters (19–20 mm) compared with the parent wild-type strain JH642 (3.95 µg mL−1 
and 10 mm, respectively) (Table.6.1). With both assays, the mutant strain inactivated in 
dltE served as an integrative vector control, and it showed susceptibilities comparable to 
the parental strain JH642 (Table. 6.1).Effect of pH on SP25A inhibiton of B. subtilis 
strains and comparisons with SP22A and SP508A. Alkaline pH promotes the hydrolytic 
removal of d-alanine from teichoic acids (MacArthur & Archibald, 1984; Hyyrylainen et 
al., 2000). As d-alanylation has the effect of masking the phosphate-negative charges of 
teichoic acids, it was speculated that alkaline pHs will increase the potential for 
interaction and therefore susceptibility of B. subtilis to cationic SP25A. Such an effect 
was observed.  In disk diffusion assays (Table.6.2), SP25A gave larger ZI diameters (30–
50%) with B. subtilis wild-type strain JH642 at pH 9.0 as compared with pH 7.0 and 5.8. 
In contrast, the ZI diameters with the dltB and dltD mutants were comparable or slightly 
larger (10–15%) at pH 9.0 as compared with pH 7.0 and 5.8 (Table. 6.2). The integrative 
vector control dltE mutant displayed the same degrees of inhibition as parental strain 
JH642 at all three pHs. The alkaline pH effect was also analyzed with syringopeptins, 
SP22A and SP508A.  With these syringopeptins, the ZI diameters were essentially the 
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same at pHs 7.0 and 9.0 with all strains tested (parental wild type and dltB and dltD 
mutants; Table 2). However, SP22A displayed higher degrees of growth inhibition of the 
dltB and dltD mutants at acidic pH. At pH 5.8, the ZI diameters were 30–40% larger for 
both mutants as compared with the cases at pH 7.0 and 9.0. Although uncertain, it is 
conceivable that the chemical stabilities of SP22A and SP508A were compromised at pH 
9.0. These findings expand upon previous reports concerning SP25A's inhibitory activity 
against B. megaterium (Iacobellis et al., 1992; Lavermicocca et al., 1997), and they 
solidify the notion that the antibacterial spectrum of the syringopeptins is confined to 
Gram-positive bacteria (Grgurina et al., 2002, 2005).  The variability in MICs (ranging 
from 1.95 to 7.8 µg mL−1) among the Gram-positive species is likely due to the evolving 
variations in cell surface structure and charge distribution that occur with these organisms 
(Peschel & Sahl, 2006). Like SP22A and SP508A (Grgurina et al., 2005), SP25A is 
inhibitory to M. smegmatis, raising the prospect that these lipopeptides may be developed 
as antimycobacterial therapeutics.   
This study shows that the anionic charges of teichoic acids are important for 
SP25A's inhibitory action against B. subtilis. In contrast, SP22A and SP508A are less 
reliant on teichoic acid charge as the dlt mutant strains were as susceptible as the parental 
wild-type strain to these syringopeptins. Two principal structural differences between 
SP25A vs. SP22A and SP508A may account for this disparity: (1) SP25A possesses 
valine instead of dehydroaminobutyrate at the fourth position of the cyclic portion of the 
peptide (from the N-terminus), and (2) SP25A has an additional three amino acids in the 
hydrophobic portion of the peptide. It is speculated that one or both of these features 
promotes interaction between the cationic charges of the SP25A cyclic peptide moiety 
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and the anionic teichoic acid phosphate groups and that such interactions are weaker or 
lacking with SP22A and SP508A. Differences in the modes of interactions of these 
syringopeptins with the cell surface were also evident by the increased level of inhibition 
by SP22A and SP508A at acidic pH, but not by SP25A. The acidic effect seen with the 
former two syringopeptins remains unexplained as well as a mechanism to account for 
their specific growth inhibition of Gram-positive bacteria. Of relevance is the observation 
that growth inhibition by positively charged polylysine is not altered in dlt mutants of 
Staphylococcus species (Peschel et al., 1999). Apparently, cationic properties alone are 
not sufficient for peptides to inhibit selectively the growth of Gram-positive bacteria even 
when lacking teichoic acid d-alanines. 
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Table 6.1. SP25A inhibitory activities against bacterial  
species and strains. 
    
Organism  1MIC   
(µg/ml)             
2ZI 
diameter(mm) 
M. smegmatis ATCC14468    
          
1.95 25 
S. aureus ATCC6538 1.95 17 
B.  megaterium ATCC14381                      1.95 13 
B. subtilis ATCC1965 3.9 11 
L. monocytogenes ATCC82302                 3.9 ND 
L.  innocua                                                 3.9 ND 
B. subtilis JH642 3.9 10 
B. subtilis dltB mutant strain (Perego, 
et al., 1995) 
0.98 19 
B. subtilis dltD mutant strain (Perego, 
et al., 1995) 
0.98 20 
B. subtilis dltE mutant strain (Perego, 
et al., 1995) 
3.9 11 
A.  faecalis ATCC8750                          >250 <1 
E.  coli ATCC25922                              >250 <1 
P.  vulgaris ATCC13315                              >250 <1 
P. aeruginosa ATCC15442               >250 <1 
S.  typhimurium ATCC14028                 >250 <1 
S.  marcescens ATCC8100                         >250 <1 
C. freundii ATCC8090                             >250 <1 
1
 MIC values  represent  two or three matching values from three experiments . 
 The initial undiluted SP25A  concentration was 5 mg per ml. 
2 Error was +/- 2 mm from duplicate determinations. 
ND= not determined 
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Table 6. 2.  Inhibition of Bacillus subtilis strains by SP25A, SP22A  
         and SP508A at pH 7.0, 5.8, and 9.0  
 
*
 ZI diameter (mm) 
 
SP25A SP22A SP508A 
 
Strain 
7.0 5.8 9.0 7.0 5.8 9.0 7.0 5.8 9.0 
  
JH642† 10 13 15 9 9 10 9 8 10 
dltB mutant‡ 19 19 22 10 13 9 8 11 7 
dltD mutant‡ 20 18 22 9 13 10 8 11 10 
dltE mutant† 11 13 14 8 9 8 9 9 8 
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Fig. 6.1. Structures of SP25A, SP22A, and SP508A. R is 3-hydroxydodecanoyl in 
SP508A and 3-hydroxydecanoyl in SP22A and SP25A 
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Fig. 6.2.  Inhibitory effects of SP25A (5 µg mL−1) on the growth of Bacillus subtilis 
strains JH642 (•), dltB mutant (○), and dltD mutant (▪) strains and the growth of  
B. subtilis JH642 in the absence of SP25A (▴). A660 nm is optical absorbance at 660 nm. 
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CHAPTER 7 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 
The need for new antifungals and fungicidal biocontrol agents is growing due to 
the narrowing spectrum of fungal targets and increasing resistance to existing antifungals 
such as amphotericin B and the azoles (11, 12).  One approach to develop novel 
antifungals is to combine known antifungal compounds.  
The focus of this research was to examine the bioactive properties of SRE and 
RLZonix against bacteria, yeast, and filamentous fungi.  Previous studies have shown that 
SRE has inhibitory activity against yeast and fungi ( MICs range, 6.25-40 µg/ml)  
(13, 7, 15) .  However, no activity against bacteria was reported.  Moreover, Haba et al. 
(1, 6) have shown that RLs have antibacterial activities against certain fungi, Gram-
negative and Gram-positive bacteria.  Although no activity against yeast was observed.  
In this study I report strong synergistic antifungal activities between SRE and RLZonix in 
the mixtures (SYRAs).  The SRE minimal inhibitory concentrations (MICs) were 
lowered when combined with RLZonix.  However, no activity was observed against 
bacteria. 
In vitro cytotoxicity and erythrocyte lysis were also investigated.  The hemolytic 
activity and cytotoxicity of SYRA was dose dependent. However, the concentrations of 
SRE in SYRA that caused hemolysis and cytotoxicity were 3 to 5 times higher than the 
MICs.  In addition, the honeybee toxicity effect of SYRA was also studied.  The results 
showed no toxicity at concentrations higher than the MICs.  The synergistic antifungal 
interaction between SRE and RL occurred at low concentrations of SRE.  As a result, the 
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effective antifungal concentration of SYRA was not toxic.  These results present new 
findings and potential uses for alternative therapeutics against pathogenic yeasts and 
fungi in various applications such as agriculture and medicine.  
To further explore their candidacies as agrofungicides, SRE and SYRA 
formulations were exposed to different temperatures and pHs, and subjected to 
autoclaving, ultraviolet light, sonication, and proteolysis.  The treated solutions were 
tested for antifungal activities and analyzed by RP-HPLC in the cases of temperature and 
proteolysis treatments.  In addition, SRE and SYRA were mixed with mineral oil and 
their activities were tested.  The overall results showed significantly high stabilities of 
SRE and SYRA under the tested conditions.  The data indicate a possible exploitation of 
SYRA as agrofungicide.   
Finally, I studied the mechanism of action of SYRA using Saccharomyces 
cerevisiae strains deficient in various steps of sphingolipid and sterol biosynthesis as a 
model.  I also studied the channel-forming properties of SYRA
 
in lipid bilayers in 
comparison with those of SRE.  Previously, it was shown that SRE acts on yeast and 
plant plasma membranes to cause numerous cellular effects with increases in cellular K+ 
efflux and transient Ca2+ fluxes among the most prominent.  The effects are consistent 
with SRE’s ability to form ion-conducting voltage sensitive channels in membrane 
bilayers.  In addition, studies with yeast have revealed that sphingolipids and sterols 
(lipids that occur predominantly in the plasma membrane) modulate the fungicidal 
activity of SRE (4, 5, 14). SRE lipidic pore formation has been proposed as the 
mechanistic basis for SRE action on membranes (10).  In this study the results suggest 
that SYRA inhibits yeast by the same mechanism as does SRE by itself.  Its antifungal 
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action is promoted by sphingolipids and sterols of the plasma membrane and involves 
pore formation.  In addition, the present data provide an explanation for the antifungal 
synergy between SRE and RLZonix.  The addition of RLZonix resulted in an increase in the 
number of membrane channels formed by SRE.  I suggest that the observed increase in 
the number of channels is due most likely to the enhancement and favorable binding of 
SRE in the presence of RLZonix.  However, the nature of interaction between SRE, RLZonix, 
and the plasma membrane is not clear.  One possibility is that the penetration of RLZonix 
into the plasma membrane attracts more SRE binding to the membrane to give an 
increase in number of channels.  It would be of interest to induce RL into the lipid 
membrane and study the attraction, insertion and orientation of SRE in the lipid 
membrane using NMR spectroscopy or circular dichroism (CD) spectroscopy (8, 3). 
Another approach will be to look directly at the SRE’s pore structure in the presence and 
absence of RL using mercury porosimetry analyses and circular dichroism (CD) 
spectroscopy (8).  It’s noteworthy to mention that the nature of the membrane plays an 
important role in how RLZonix binds and inserts into the membrane (2).  Perhaps studying 
the characterization of a single channel in membrane bilayers using different ratios of 
lipids and solid-state NMR spectroscopy will help to define the interaction of SRE and 
RL with the plasma membrane and the effects of membrane composition on their 
antimicrobial activity.  
 In conclusion, these studies show strong synergism between SRE and RLZonix 
against fungi and yeast including phytopathogenic species.  The antifungal spectrum, low 
toxicity, chemical and physical stabilities suggests that SYRA is a potential candidate for 
fungicidal agricultural applications and antifungal therapy in medicine.  However, 
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additional studies such as in vivo examination of SRE and RL mixtures are needed to 
evaluate the significance of the combination as a potential antifungal therapy or 
agricultural fungicide.  To illustrate SYRA candidacy as antifungal agent, SYRA can be 
tested against aspergillosis and candidiasis in animal models.  Additionally, further 
studies in pharmacokinetics and pharmacodynamics can be performed to develop 
strategies dosing for an optimize treatment (9).  Furthermore, to explore the possibility of 
SYRA as a biocontrol agent against phytopathogenic fungi, infected plants or infected 
seeds can be used as a model.  In addition, SYRA can also be tested as a postharvest 
control agent by studying the effect of SYRA on infected and wounded fruit.  
The studies reported here offer a new approach for developing new antifungal 
agents. For example, combining rhamnolipids with other lipodepsipeptides such as 
syringotoxins, syringostatins, and syringopeptins and with other amphipathic compounds 
may lead to discoveries of novel and effective fungicidal formulations for future 
applications in agriculture and medicine.  
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APPENDIX A 
 
ANTIMICROBIAL ACTIVITY OF SP25A- RLZonix AND GRAMICIDIN- RLZonix 
COMBINATIONS 
 
Disk diffusion tests were done according to NCCLS methods with modification 
{Washington, 1995 #55}.  Tested organisms were grown in appropriate media (Bacteria 
strains were grown on Luria-Bertani medium except S. aureus was grown on Mueller-
Hinton medium and R. pilimanae on potato dextrose broth ( PDB) for 24 to 48 h, and the 
cell densities were adjusted to 0.5 McFarland standard.  A 100 µl aliquot of each culture 
was spread over the surface of the appropriate agar growth medium as a thin film.  A 6 
mm diameter sterilized paper disk was placed and pressed down onto the agar {Perego, 
1995 #31}.  The SP25A- RLZonix, and gramicidin-RLZonix combinations were prepared by 
adding SP25A or gramicidin (both at 1 mg/ml) together with RLZonix (1 mg/ml) in ratios 
of 1:3 [wt/wt] ,1:2 [wt/wt] and 3:1 [wt/wt], respectively.  Ten µl of the mixtures were 
applied onto the disks.  The plates were incubated for 24 to 48 h and the zones of 
inhibition were measured.  
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Table. Antimicrobial activities of SP25A (1mg/ml)- RLZonix (1mg/ml) combinations. 
 Zone of inhibition (mm) 
 SP25A RLZonix  SP25A-RLZonix  
1:2 
SP25A-RLZonix  
1:3 
SP25A-RLZonix  
3:1 
R. pilimanae 10 >1 >1 >1 9 
S. aureus 20 >1 9 >1 15 
B. subtilis 12 >1 8 >1 9 
E. coli >1 >1 >1 >1 >1 
 
 
Table. Antimicrobial activities of gramicidin (1mg/ml)-RLZonix (1mg/ml) combinations. 
 Zone of inhibition (mm) 
 
Gramicidin RLZonix  Gramicidin- 
RLZonix  
1:2 
Gramicidin- 
RLZonix  
1:3 
Gramicdin- 
RLZonix  
3:1 
R. pilimanae >1 >1 >1 >1 >1 
S. aureus 25 >1 15 10 18 
B. subtilis 23 >1 10 >1 15 
E. coli >1 >1 >1 >1 >1 
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APPENDIX B 
 
 
MECHANISM OF ACTION OF SP25A- RLzonix COMBINATION  
 
 
To study the influence of RLZonix on SP25A interaction with the plasma 
membrane, I examined the membrane channel forming properties of SP25A in the 
presence and absence of RLZonix.  The effects on ion conductance across planar lipid 
bilayers were measured.  The figure shows time courses of the integral macroscopic 
conductance of the bilayers doped with SP25A alone and SP25A with RLZonix.  The 
results showed that the negative potential application drove the increase of the membrane 
conductance. Remarkably, the addition of RLZonix to cis side of the bilayer caused no 
changes in the membrane conductance.   
Lipid bilayer electrophysiological experiments were performed using 1,2-
dioleoyl-sn-glycero-3-phosphorylcholine (DOPC), (Avanti Polar Lipids) as previously 
described (Malev, et al., 2002) (Blasko, et al., 1998).  Solutions of 0.1 M of NaCl were 
buffered with 5 mM MOPS (Sigma) to pH 6.  Bilayer lipid membranes were prepared by 
the monolayer-opposition technique (Montal & Mueller, 1972) on a 50–100 µm diameter 
aperture in the 10 µm thick Teflon film separating two (cis and trans) compartments of a 
Teflon chamber (Bezrukov & Vodyanoy, 1993) (Montal & Mueller, 1972).  The 
membrane-forming solution was DOPC.  A pair of Ag/AgCl electrodes with agarose/2 M 
KCl bridges was used to apply transmembrane voltages and to measure single channel 
currents.  Current measurements were carried out using an Axopatch 200B amplifier 
(Axon Instruments) in the voltage clamp mode.  The data were filtered with a low-pass 8-
pole Model 9002 Bessel filter (Frequency Devices) at 1 kHz and directly recorded into 
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computer memory with a sampling frequency of 5 kHz.  Data were analyzed using 
pClamp 9.2 (Axon Instruments) and Origin 7.0 (Origin Lab).  Single channel 
conductance was calculated as the mean single-channel current divided by the applied 
transmembrane voltage.  All experiments were performed at room temperature. 
SP25A (1 µg/ml ) and RLZonix (4 µg/ml) were added to the aqueous phase as fellows : 
5- At t=0, SP25A was added to cis side compartment  
6-  At t=0, RLZonix was added to cis side compartment, then at t=10 min, SP25A was 
added to the same side. 
 
 
 
 Time courses of the ion conductance of the bilayers doped with A)- SP25A applied 
to cis side.  B)- SP25A and RLZonix applied to Cis side. 
 recorded at the applied voltage of –50 mV 
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APPENDIX C 
 
 
ANTIFUNGAL ACTIVITY OF PSEUDOMONAS SYRINGAE PV SYRINGAE  
 
SYRINGOMYCIN EXTRACT AND RHAMNOLIPID   
 
COMBINATIONS 
 
 
Syringomycin extracts were purified from P.syringae pv.syringae strain M1 by 
the method of Bidwai et.al {Bidwai, 1987 #242}.  Five-hundred ml-capacity Erlenmeyer 
flasks containing 250ml of PDB medium were inoculated with 1 ml of an actively 
growing culture.  The flasks were incubated at room temperature without shaking for 7 to 
14 days.  The flasks were chilled to 4°C and 250 ml of cold acidified acetone was added 
(4 ml HCl per litter acetone).  The debris and cells were removed by centrifugation.  The 
supernatant was then concentrated by rotary evaporation to 400 ml. Then, 600 ml of 
acetone were added and the suspension was stirred overnight at 4°C. Finally, the 
suspension was centrifuged and the supernatant was removed and concentrated, then 
diluted to 1 l with 0.l% trifluoroacetic acid (TFA).  The TFA solution was applied to an 
Amberlite XAD-2 (20 to 50 mesh) column (3×25 cm). The crude extract was eluted with 
0.1% TFA using a nonlinear gradient of 2-propanol.  The 2-propanol was removed using 
a rotary evaporator and the solution was concentrated and lyophilized.  The sample was 
dissolved in 15 ml of water:acetone (40:60 v/v). The final extract was diluted 2-1 to 2-4 
with water before mixing (1:1 v/v) with 1 mg per ml rhamnolipid (Zonix or RLZonix) . 
Commercial RLZonix) was obtained from Jeneil Biotech, Inc.  RLZonix is an 8.5% (wt/vol) 
solution of rhamnolipid analogs in water. Two forms of rhamnolipids are in RLZonix, R1 
(C26H48O9) has the molecular formula of α-L-rhamnopyranosyl-β-hydroxydecanoyl-β-
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hydroxydecanoate, and R2(C32H58O13) is 2-O-α-L-rhamnopyranosylα-L-
rhamnopyranosyl- β  hydroxydecanoate. 
The combinations were prepared by mixing RLZonix with diluted syringomycin 
extract.  
 Method similar to those described by the NCCLS protocols for antifungal testing 
{Washington, 1995 #55} was used. R. pilimanae was grown on PDB medium and 
adjusted to 5×104 CFU per ml {Shin, 2003 #63} {Johnson, 1999 #65}.  A 100µl of the 
culture was transferred onto solid agar medium. The culture was spread over the surface 
as a thin film {Shin, 2003 #63}. Four mm diameter sterilized paper disk was deposited on 
the surface. Different mixtures of diluted crude extract and RLZonix were prepared and 
applied on a disk (7 to 10 µl aliquots).  The plate was incubated at 28°C for 24 h and the 
zone of inhibition was measured {Cuenca-Estrella, 2003 #61}. 
 The antifungal activity of crude extract is shown in Table (Appendix C). The 
crude extract and RLZonix showed strong antifungal synergism against R. pilimanae.  The 
zones of inhibition of the combinations were greater than the crude extract applied alone. 
The strongest activity was observed when 3 mg/ml of RLZonix was combined with 1/16 of 
the crude extract.  
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Table (Appendix C). Antifungal activity of syringomycin extract and RLZonix 
combinations against R. pilimanae. 
 
  Zone of inhibition (mm) 
RLZonix  
(1 mg/ml)  
 
-- 18.75 3 0.850 0.250 
Dilution of syringomycin 
extract  
(1 mg per ml) in mixed with 
RLZonix  
(1 mg/ml) 
-- -- -- -- -- 
1 15 ND ND ND ND 
½ 14 ND ND ND ND 
¼ 13 38 30 20 15 
1/8 12 44 42 21 15 
1/16 12 36 45 20 15 
 
ND: not determined 
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APPENDIX D 
 
 
POSTHARVEST CONTROL OF FUNGI USING SRE AND SYRA 
 
 
 Postharvest fruit biocontrol assays were done by methods described by Bull et al. 
{Bull, 1998 #151} and   Zhou et al. {Ting Zhou, 2001 #261} with modification. Peaches 
(variety E lberta) free of wounds and pesticide-free were obtained form a local home 
garden (Jon Takemoto, North Logan, Utah).  The fruits were washed using sterile water. 
The fruits were wounded using a sterile steel rod and 20µl of spore (1× 108 spore/ml) 
suspension was placed in the wound and allowed to dry.  SRE ( 40 µg/ml) and SYRA  
( SRE 40 µg/ml, RLZonix 120 µg/ml) were then applied.  The fruits were kept at room 
temperature and photographs recorded after 3 days.  Each tray held three fruits and each 
experiment was done three times.   
The treatment with SRE and SYRA provided significant reduction in the growth 
of tested fungi and it was effective in controlling Botrytis cinerea and  Rhizopus stonifer 
on peaches.  
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Fig. Biocontrol assay. Botrytis cinerea (A), Rhizopus stonifer (B), Penicillium oxalicum 
(C). 20µl of spore were dropped on the wound. The 20µl of SRE (40 µg/ml) and SYRA  
( SRE 40 µg/ml, RLZonix 120 µg/ml ) were applied after the spore suspension was dried.  
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